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Extensive research have been conducted to dissect the rapidly evolving 
mechanism of HIV-1 neuropathogenesis, and to investigate the viral 
reservoirs in the central nervous system (CNS), which is considered as a 
major barrier for the viral eradication. These efforts have been hindered due to 
the paucity of relevant animal models of progressive HIV-1 brain infections.  
 Therefore, we developed a brand new mouse model reconstituted with 
both a human immune system and human glia (primarily astrocyte and 
oligodendrocyte lineage) in the brain. We transplanted newborn 
NOD/SCID/IL2Rγc−/− (NSG) mice with human neural progenitor cells (NPCs) 
in the lateral ventricle and hematopoietic stem cells (HSCs) in the liver at 
birth. Human astrocytes repopulated the white matter and periventricular 
mouse brain regions in an anatomically symmetrical manner, with the highest 
level of reconstitution in corpus callosum and periventricular region, and 
relatively low levels in other regions like frontal cortex, striatum and brain 
stem. Human glial engraftment induced transcriptional changes associated 




angiogenesis, and axon growth, ion channel activities, compared to non-
reconstituted mice, as determined by next generation RNA sequencing. 
We then investigated the effects of HIV-1 infection on immune and glial 
cells pathological and molecular changes. The immune analyses of these 
HIV-1-infected mice showed increased meningeal and perivascular infiltration 
by human HLA-DR+ cells and surveillance by activated immune cells in brain 
tissue. The species-specific transcriptome analysis revealed alterations that 
were linked to interferon (IFN) type 1 and 2 signaling pathways (STAT1, 2, 
IRF9, MX1, ISG15, IFI6, CMPK2) and a range of host antiviral responses. 
Differentially expressed mouse genes in the hippocampus reflected tissue 
remodeling while down-regulated human genes were linked to altered cell 
growth, glial cytoskeleton reorganization, oligodendrocyte differentiation and 
myelin ensheathment (MBP, MOBP, PLP1, MAG and ZNF488). The results 
overlapped with the disease profile observed by others in human HIV-1 
encephalitic brains. Therefore, this new model provided a promising future for 
study of human-specific viral-immune-glial interactions and discovery of new 
therapeutic targets for HIV-1 nervous system infection. 
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1.1 HIV-associated neurocognitive disorders (HAND) and the 
neuropathogenesis of HIV-1 infection  
The human immunodeficiency virus (HIV) is a member of retroviruses that 
primarily infect human CD4+ T lymphocytes and macrophages. As the viral 
replication persists, a progressive depletion of CD4+ T cells and the 
consequent immune suppression render the hosts extreme vulnerability to 
viral-induced tumors and opportunistic infections caused by bacteria, fungi, 
parasites, and virus [1]. Antiretroviral therapies have been developed over the 
last decade aiming at suppressing viral load and preserving immune function. 
With the advent of combined antiretroviral therapies (cART), the mortality rates 
in people infected with the HIV have been profoundly lowered, so has been the 
frequency of drug resistance [2]. While this treatment has successfully reduced 
the prevalence of AIDS and prolonged patients’ lifespans, so that HIV infection 
is now primarily managed as a chronic disease [3], a serious comorbidity that 
remains prevalent in nearly 30% of cART-treated HIV-infected individuals are 
the HIV-associated neurocognitive disorders (HAND), a spectrum of 
neurological complications that range from asymptomatic cognitive 
impairments to severe dementia [4]. Although the severe cases of 
HIV-associated dementia (HAD) are becoming increasingly uncommon with 
the sustained suppression of peripheral viral load, milder forms of HAND 
remain major concerns for HIV-infected individuals because of the persistent 
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inflammation in the brain and the consequent impairment in their ability of 
performing daily activities [5, 6]. In severe instances, HAND can contribute to 
increased mortality in HIV-infected individuals because their cognitive 
dysfunction results in cART noncompliance [7]. 
Several processes have been suggested to contribute to the pathogenesis 
of HAND. These include: (1) Immune activation and viral infection of 
mononuclear phagocytes (MPs) in the central nervous system (CNS), 
including microglia and macrophages, create a pro-inflammatory 
microenvironment, which imposes overwhelming stress signal upon neurons 
and glia; (2) Neurotoxic viral products secreted by these brain MPs directly 
cause neuronal damage and dropout; (3) co-existing factors such as aging, 
drug abuse, Hepatitis virus B/C (HBV/HCV) co-infection, and low 
socioeconomic status, also contribute to this devastating complication of HIV 
disease. These mechanisms are discussed in detail below. 
 
1.1.1 Immune activation and neuroinflammation 
HIV infectious particles transport and immune cell migration across the BBB 
are critical processes in HIV-induced CNS pathology. Mounting evidence has 
shown HIV crosses the blood-brain barrier both as cell-free virus and using 
infected macrophages as Trojan horses [8, 9]. It is widely recognized that in 
the absence of a direct infection of neurons, indirect mechanisms play a major 
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role in HAND neuronal dysfunctions and death. And indeed, the degree of 
correlation between cognitive impairment and cerebrospinal fluid viral load are 
not particularly robust, suggesting that the pathophysiology of HAND involves 
more than just the immediate neurotoxicity of the virus. 
HIV-infected macrophages and T cells not only infect brain resident cells 
upon migration into the CNS, but also trigger a vigorous innate immune 
response that drives the release of proinflammatory cytokines such as TNF-α, 
IL-1β, and virotoxin-associated neurotoxic responses [10]. This process is 
perpetuated by autocrine and paracrine amplification of cytokine activities and 
activation of microglia and astrocytes, causing the release of more 
inflammatory cytokines. In addition, chemokines such as CCL2 and CXCL8 
released from infected MPs can further attract infiltration of infected 
macrophages cross the blood-brain barrier (BBB). This autonomous 
amplification of cytokine and chemokine cascades would eventually interrupt 
astroglial function and integrity, compromising the metabolic function and 
homeostasis of the CNS (Figure 1.1). In addition to the functions mentioned 
above, astrocyte is a significant component of the BBB, ensuring the immune 
privilege of the brain, which are altered in HAND patients. The impact of 
astrocyte infection might be substantial because these cells demonstrate 
aberrant intracellular signaling and abnormal interactions with the brain 
endothelial cells of the BBB [11]. Reactive astrogliosis or astrocytes 
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compromised by virus and inflammatory factors cannot consolidate BBB 
properly, which would allow increased numbers of HIV-infected or activated 
monocytes or lymphocytes to traffic into the perivascular space, thereby 
exposing the brain to additional HIV-infected cells and proinflammatory insults. 
 
1.1.2 Neurotoxic viral products 
Another key process that mediates neurotoxicity is the release of soluble 
neurotoxic viral proteins such as gp120, gp41, Tat, and Nef. As mentioned 
above, activated MPs support a persistent viral infection and chronic 
inflammation, serving as a major source of neurotoxic proteins that if produced 
and accumulated in abundance, affect neuronal function. Studies of HIV gp120 
transgenic mice indicated gp120 expression in astrocytes can lead to 
microgliosis and astrogliosis similar to that seen in human HIV 
neuropathological findings [12]. Other studies also showed gp120 increased 
BBB permeability, and therefore the infiltration of peripheral immune cells. 
Furthermore, exposure to gp120 in vitro results in neuronal dendritic damage 
and apoptosis of human primary neurons [13]. Other regulatory proteins of HIV 
have also been found toxic to the CNS. In fact, mainstream cART regimens 
inhibit HIV replication by targeting HIV protease or HIV reverse transcriptase. 
Because of this, the drugs do not block production of the early viral proteins 
Tat and Nef [14]. This is especially problematic for Tat because, despite of the 
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presence of successful cART-mediated suppression of HIV replication, 
infected cells still release Tat protein into the extracellular space where it can 
exert neurotoxic effects by interacting with neighboring cells [15, 16]. Tat has 
also been shown to interact with astrocytes and disrupt the tight junctions of 
the BBB. As introduced in the previous paragraph, increased permeability of 
the barrier can further augment neuroinflammation. Postmortem findings in 
HIV patients brains with HAD showed expression of Nef in hippocampal 
neurons, suggesting the role played by this protein in impairing hippocampal 
neurons and consequent memory deficit in these patients [17]. It is reported 
Nef leads to astroglial and neuronal cell death through both direct damage and 
indirect induction of CXCL10 [18]. 
 
1.2 Brain microenvironment under homeostatic conditions 
Brain microenvironment is closely monitored and regulated by different cellular 
components in the CNS. Among them, astrocytes and microglia are the key 
players. Astrocytes function as the pivot in maintaining CNS homeostasis, 
regulating neurotransmitter release, stabilizing energy metabolism and forming 
BBB. Additionally, emerging evidence is indicating that astrocytes participate 
in the local innate immune responses mediated by a variety of receptors 
involved in innate immunity, including Toll-like receptors, nucleotide-binding 
oligomerization domains, double-stranded RNA-dependent protein kinase, 
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scavenger receptors, mannose receptor and components of the complement 
system [19]. Following activation, astrocytes are endowed with the ability to 
secrete soluble mediators, such as CXCL10, CCL2, interleukin-6 and BAFF, 
which have an impact on both innate and adaptive immune responses 
[20].  Microglia are the local tissue macrophages governing local innate and 
adaptive immune response, conducting immunosurveillance and scavenging 
endogenous and exogenous risk factors in the CNS [21]. Recent studies also 
suggest that microglia actively engulf synaptic material and play a major role in 
synaptic pruning during postnatal neural development [22, 23]. These findings 
imply microglia contribute to the synaptic maturation and the deficit of which 
could result in some neurodevelopmental disorders. Other cellular 
components like pericytes and vascular endothelial cells also play critical roles 
in maintaining the integrity of the BBB and regulating brain microenvironment 
within a precisely confined limit.  
 
1.3 Brain microenvironment altered by HIV-1 and other infectious agents 
and endogenous damage1 
Maintaining the central nervous system microenvironment after injury, infection, 
inflammatory and degenerative diseases is contingent upon adequate control 
																																																						
1	 Content in chapter 1.3 and 1.4 were reproduced with permission from Weizhe Li, 
Hsin-I Tong, Santhi Gorantla, Larisa Y Poluektova, Howard E Gendelman, Yuanan Lu. 
Neuropharmacologic Approaches to Restore the Brain’s Microenvironment; J Neuroimmune 
Pharmacol. 2016, Jun 28; Copyright Springer.	
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of glial homeostatic functions. Disease is caused by microbial, environmental 
and endogenous factors that compromise ongoing nervous system functions. 
The final result is neuronal injury, dropout and nerve connection loss, and 
these underlie the pathobiology of Alzheimer’s and Parkinson’s disease, 
amyotrophic lateral sclerosis, stroke, and bacterial, parasitic and viral 
infections. However, what promotes disease are homeostatic changes in the 
brain’s microenvironment affected by innate glial immune pro-inflammatory 
and adaptive immune responses. These events disturb the brain’s metabolic 
activities and communication abilities. 
For infectious, degenerative and inflammatory disorders of the CNS, 
microglial responses directly participate in disease. This occurs as a 
consequence of the cells’ reaction to infectious, immune and degenerative 
processes [24, 25]. First, viral infections, for example, can lead to a 
parainfectious encephalomyelitis. This is commonly referred to as an acute 
disseminated encephalomyelitis (ADEM) where disease is driven 
pathobiologically by antigen-antibody attack. Autoimmunity occurs as a 
consequence of generalized neuroinflammation in the brain and spinal 
cord with profound myelin damage and white matter destruction. ADEM is 
commonly triggered after infection with a spectrum of viruses that include, but 
are not limited to influenza, measles, mumps, rubella, varicella zoster, Zika, 
Epstein Bar, cytomegalo-, entero- and herpes simplex viruses. ADEM can also 
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be driven by vaccinations [26, 27]. In both instances, brain injury is commonly 
self-limited, and permanent neurological sequel can occur but not 
commonly. Second, direct viral invasion of the CNS induces disease as a 
consequence of productive infection in neurons or accessory glial or 
endothelial cells. The process is active within the nervous system parenchyma. 
Such invasion is dependent on the pathogen, the immune status of the host 
and related genetics, and host immune responses. Such pathogenic events 
are commonly associated with significant morbidity and mortality. The former 
is seen with altered levels of consciousness and focal neurological symptoms 
commonly include seizures [28]. A third cause of encephalitis is linked to 
inflammatory responses that occur as a consequence of viral infection of 
accessory cells and notably, monocytes, macrophages and microglia [8, 29]. 
This directly involves neuronal destructive activities induced by viral and 
cellular neurotoxic proteins [30]. A singular example of accessory cell 
infection-associated encephalitis is HIV-1 infection. Apropos of HIV, a vigorous 
innate immune response occurs as a direct consequence of brain MP; 
infection that drives pro-inflammatory and virotoxin-associated neurotoxic 
responses [8, 10]. This is perpetuated by autocrine and paracrine amplification 
of cytokine activities and by ongoing infection in the setting of a failure of 
immune responses or in patients where antiretroviral therapy has not been 
initiated [31]. Neuronal loss in HIV-1 encephalitis is strongly associated with 
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synaptic and dendritic damage [32]. Overt synaptic loss is in turn linked to 
severe cognitive impairment and brain viral load. Interestingly, levels of virus 
can vary dependent on brain region and underlies that it is the inducer of 
immune secretory factors, the perpetrators of disease [33]. Indeed, the 
development of dementia commonly but not always is associated with virus 
[34]. Interestingly, compensatory immune responses can restrict virus and 
attenuate disease; also, the advent of combination antiretroviral therapy has 
limited viral infection in the brain and facilitated host antiretroviral activities. 
Nonetheless, given the limited penetrance of antiretroviral drugs across BBB 
and comorbid conditions such as aging, drugs abuse and coinfection of 
hepatitis viruses in the HIV-infected population [35], persistent 
neuroinflammation and viral reservoirs hiding in the brain remain to prevent the 
CNS function from restoring [36, 37]. 
For the degenerative Alzheimer’s and Parkinson’s diseases (AD and PD), the 
accumulation of misfolded, oxidized and aggregated proteins affect 
neuroinflammation and rapidly lead to neuronal dysfunction [38-40]. Control of 
disease can also be associated with inflammation and immunity but how this 
occurs and can be harnessed for therapeutic gain is less clear [41, 42]. In 
general terms, attenuation of inflammation either by drugs or by relevant 
adaptive immune responses can facilitate disease outcomes, but the corollary 
provides opposite endpoints. Altogether, with the importance of 
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neuroinflammation as a cause for a range of disorders of varying etiology, a 
primary therapeutic goal is the control of brain’s microenvironment regardless 
of the disease. Obviously, the removal of the root cause such as the infectious 
agent or the misfolded proteins remains primary. This can be realized by 
therapeutics and vaccination strategies [43-46]. However, what must follow is 
the restoration of the brain’s innate immune function in sustaining its metabolic 
function and homeostasis. This is what underlies restorative neuronal vitality 
[47, 48]. 
 
1.4 Adjunctive strategies for restoration of brain homeostasis for HIV 
infection of the brain 
Here, we discuss the means to achieve the goals of controlling the brain’s 
microenvironment. This will be highlighted through others and our own 
developments of therapeutics that are aimed towards restoring neural 
homeostasis. Underpinning this goal is a singular limitation that rests in drug 
penetrance across the BBB and as such access of therapeutic agents to 
damaged brain areas [49]. To this end, questions still exist on how BBB 
disruption occurs and can be reversed, how altering vascular channels can 
occur, and how chemical modification of drugs can be better developed to 
maximize therapeutic delivery [50-52]. Although each approach has its 
limitations and drawbacks, several chemical modifications of drugs to increase 
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lipophilicity to move through lipophilic BBB, disguising them with lipophilic 
molecules to make pro-drugs, attaching targeting molecules to get the drugs to 
pass through the BBB, and packaging them into nanoparticles or exosomes 
were investigated [53-55]. Yet another means rests in the delivery system 
where we can harness MP as carriers of antiviral drug nanoparticles as well as 
disease fighting proteins and nucleic acids [56]. The delivery of such agents 
across the BBB remains a singular goal [57, 58]. Overall, we discuss the 
feasibility of modulating the CNS microenvironment for therapeutic benefit. We 
also reviewed the recent advances in delivery of therapeutic agents to the 
brain with a particular emphasis on the means to restore the brain’s 
microenvironment during disease using a spectrum of adjunctive therapies that 
include those that attenuate inflammation and deliver growth factors to the 
sites of injury [59-61]. 
 
1.4.1 Anti-inflammatory therapies  
Neurodegenerative conditions like AD, PD and HAND are accompanied by 
over active inflammatory responses that herald onset and tempo of disease 
progression [42, 62]. The etiologies of each of these disorders reside in distinct 
agents that include aggregation of misfolded protein, immune attack and viral 
infection that lead to a commonly deleterious consequence that interrupts the 
homeostasis of the local microenvironment. Microglia, a sensor and scavenger 
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for pathological events in the CNS, become rapidly activated in response to 
environmental, infectious and immunotoxin signals. These include in the case 
of neurodegenerative diseases with misfolded proteins. Microglia 
subsequently undergo a series of morphological, molecular and secretory 
changes that affect the brain’s microenvironment [63, 64]. Additionally, the 
interplay between microglia and astrocytes further polarizes the former 
towards a neurotoxic phenotype [65]. Such changes in phenotype can affect 
the brain’s microenvironment by producing a pro-inflammatory milieu that 
speeds neuronal injury and ongoing disease pathogenesis [66]. Although the 
CNS was historically considered to be immune-privileged, activation and 
transformation of resident and circulating immune cells in pathogenesis of 
neurodegenerative diseases indicate that brain hemostasis and immune 
system status are tightly coupled. Evidence also suggests that there are 
lymphoid controls operative in the brain [67]. Nonetheless, MP activation and 
subsequent induction of chemokines like CCL2, CXCL8 and pro-inflammatory 
mediators such as inducible nitric oxide synthase (iNOS), tumor necrosis 
factor–α (TNF-α) and interleukin-6 (IL-6) collectively serve to speed the 
infiltration of circulating immune cells into the CNS [68, 69] (Fig. 1.1). The 
migration of effector memory T cells from the periphery generates 
leukocyte-microglial crosstalk that exacerbates neuroinflammation and 
restricts neuronal survival [56]. Another important player of immune origin 
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contributing to the pro-inflammatory signals is mast cells, which are found in 
most tissues; they transverse compromised BBB to become CNS residents. 
Mast cell–glia communication also opens new perspectives for the 
development of therapies targeting neuroinflammation by differentially 
modulating activation of non-neuronal cells that normally control neuronal 
sensitization [70]. Immunopharmacologics are being developed as 
neuroprotective strategies for disease either to block the attraction of the 
circulating immune cells, T cells, macrophages and mast cells to the CNS by 
restoring the BBB or to induce anti-inflammatory responses in the CNS [67]. 
Disease-modifying treatments can control inflammation and restore neural 
function (Fig. 1.2, 1.3). Such adjunctive therapies take into account that 
modulating both innate and adaptive immune responses are necessary for 
success in ameliorating an inflammatory CNS microenvironment and as such 
restore neuronal function during disease [71]. 
The pragmatic question that has been continuous over many years is why 
have so many anti-inflammatory therapies failed to improve disease outcomes 
for neurodegenerative disorders? [72]. This is believed to be due to the overall 
pro-inflammatory microenvironment that remained uncontrolled or even 
deteriorated as diseases progress, which counteracts the benefits from the 
blockage of over-activated excitatory synapses. In this regard, comprehensive 
management of neuroinflammation needs be taken at a more fundamental 
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level. MP, microglia and macrophages, activated by HIV-1 facilitate 
neuroinflammation by upregulating pro-inflammatory cytokines and 
monocyte-chemotaxis signals, which in turn further recruit circulating MP to the 
diseased brain [73]. For example, for HAND, attempts were made to use 
memantine, an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) 
receptor, as an adjunctive agent to antiretroviral therapies aimed at reducing 
excitatory neurotoxicity, but if failed to improve cognitive functions [31]. This 
was seen in a phase II double-blinded, randomized, placebo- controlled trial, 
despite positive preclinical investigations [74]. 
Another example is with a mixed lineage kinase-3 (MLK3) inhibitor. MLK3, 
a widely expressed kinase in neurons [75], astrocytes [76], microglia [77] and 
myeloid lineage cells [78], regulates the c-Jun N-terminal Kinase (JNK) MAPK 
and p38 signaling pathways, which is tightly related to monocyte chemotaxis 
via CCL2 and CXCL8 and to cytokine production by microglia and brain 
macrophages [79, 80]. It has been demonstrated that HIV Tat and gp120 
protein can induce autophosphorylation at the activation loop of MLK3 in 
primary rat neurons and human monocytes, which can be abolished by 
CEP-1347, a large molecular inhibitor of MLK3 [81]. Further in vivo studies 
also indicated the neuroprotective effect of CEP-1347 with apparent reduction 
in microgliosis, neuronal loss and preserved dendritic integrity in an HIV 
encephalitis (HIVE) model [60]. The neuroprotective attribute of CEP-1347 has 
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also been shown in studies of other neurodegenerative disorders such as 
Huntington’s disease [82, 83]. The promising results obtained in animal 
models of neurodegenerative disorders stretched to CEP-1347 clinical trials in 
PD patients. However, a phase II clinical trial concluded CEP-1347 as 
ineffective treatment in early PD [84]. Symptoms of PD start when about 70–
80 % of striatal dopamine and about half of nigral dopamine neurons have 
been lost [85]. Neuronal loss occurs generally over the course of a preclinical 
period of several years [86]. Therefore, the irreversible degeneration may have 
started before CEP-1347 could be given in this set of patients; moreover, 
single neuroprotective agent may not be sufficient to reverse the disease 
progression. Implementation of strategies for primary prevention will require 
the identification of markers that would permit early diagnosis prior to the onset 
of symptoms. Another concern resides in the limited distribution of CEP-1347 
to the CNS due to its naturally polar structure and large molecular weight [87]. 
Indeed, a new MLK-3 inhibitor, URMC-099, with a favorable chemical profile 
and CNS penetrant property was designed. This compound demonstrated a 
significant amount of the neuroprotection imparted by inhibiting MLK3 in 
immune cells and microglia [88]. 
 
1.4.2 Combination adjunctive and antiretroviral strategies 
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The effectiveness of CEP1347 and URMC-099 in the control of 
neuroinflammation and protecting neurons from injury is significant with the 
latter showing dramatic effects in the treatment of experimental HAND models 
[60, 88]. The known etiology and definite onset point of HAND possibly render 
this an advantage. Nevertheless, the power of these in vivo studies was 
partially limited until very recently when URMC-099 was shown to have both 
neuroprotective and unique antiretroviral effects [89]. Indeed, during studies to 
extend the half-life of crystalline nanoformulated antiretroviral therapy 
(nanoART), URMC-099, which was originally developed as an adjunctive 
neuroprotective agent, was demonstrated to broaden antiviral responses and 
improve ART biodistribution. Co-administration of long-acting ritonavir-boosted 
atazanavir (nanoATV/r) nanoformulations with URMC-099 not only reduced 
viral load and the numbers of HIV-1 infected CD4+ T-cells in lymphoid tissues 
but sustained drug levels in reservoirs of viral infection. These results were 
realized more than either drug alone when administered in infected humanized 
NOD/SCID/IL2Rγc−/− mice and paralleled the formation of drug depots within 
the reticuloendothelial system. The autophagosome appears to be that depot 
and to lead to the sequestration of nanoATV/r in Rab-associated recycling and 
late endosomes [89, 90]. These results provide an example for how unique 
immune modulatory reactions can also improve antiretroviral responses. As 
such the drug combinations are being developed beyond protease inhibitors to 
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involve other drug classes that include integrase inhibitors to facilitate 
cell-based viral clearance. 
 
1.4.3 Cell-based gene and immune modulatory therapies  
Well known is the fact that MP can cause BBB breakdown following brain 
inflammation, migrating toward the inflammation site via processes known as 
diapedesis and chemotaxis [91]. Relying on the natural inflammatory 
responses, macrophages have been widely applied for the active delivery of 
therapeutic agents, including nucleic acids, peptides, drugs and enzymes, to 
the brain. Indeed, delivery of nanoART using macrophages as carriers has 
significantly increased drug concentration and reduced HIV-1 replication in the 
diseased compartments of HIVE rodents [92]. Limited effect on the ongoing 
neuroinflammation in this study, however, reinforced the importance of 
combining immune-modulatory therapy to restore the brain’s innate immune 
and metabolic homeostasis. 
Gene therapy is the therapeutic approach of precise manipulation of the 
host genome, ultimately the function of targeted cells. Recent studies and 
clinical trials have employed a variety of vehicles to deliver protective genes to 
the CNS [93, 94] (NCT01446614, NCT01883661). With the known 
effectiveness of soluble TNF-receptor (sTNFR) in the treatment of peripheral 
autoimmune and inflammatory conditions including rheumatoid arthritis [95], 
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we reasoned that a parallel approach could be applied for HIV infections of the 
nervous system where a pro-inflammatory environment seen within the brain 
incites neuronal-drop out and related cognitive dysfunction. We showed that 
the bicistronic plasmid construct, sTNFR-Fc-eGFP, expressing the sTNFR-Fc 
fusion protein and the green fluorescent protein (GFP) was suitable for stable 
expression of sTNFR-Fc in human macrophages and neuronal cells as a 
potential therapy for neuroAIDS [96]. To this end, we transduced bone 
marrow-derived macrophages (BMDM) with the defective lentiviral vector 
encoding sTNFR:Fc-eGFP (MOI =15). In BMDM sTNFR-GFP (below this used 
as shorter abbreviation of transcript) was expressed with efficiency greater 
than 45 % of transduced cells (Fig. 1.4a). The transduction efficiency of the 
injected BMDM was confirmed by flow cytometry (ten days post transduction), 
which demonstrated on average more than 45 % of BMDM were GFP+ 
(Fig. 1.4b). Two hours prior to adoptive transfer of the recombinant 
sTNFR-GFP transduced BMDM, the immune 
deficient NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice were injected 
intracranially (i.c.) in the caudate putamen with 2 × 105 HIV-1ADA infected 
monocyte-derived macrophages (MDM) as described previously [92]. This 
procedure induced encephalitis referred to as HIVE, which paralleled what is 
operative, in infected patients (Fig. 1.4c). 
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Adoptive transfer of sTNFR transduced BMDM showed no change in 
numbers of HIV-1p24 positive infected cells or the intensity of astrocyte 
responses, but a modest reduction in microglial staining was evident 
(Fig. 1.5a). In this survey histopathological analyses of brain sections were 
acquired at sites of HIV-infection-mediated injury. Here, Iba-1 staining showed 
that adoptive transfer of sTNFR-GFP transduced BMDM attenuated 
microgliosis in brain areas surrounding the injection sites of HIV-1 infected 
MDM, when compared to adoptive transfer of control BMDM. In Fig. 1.5b, 
neurofilament staining was evaluated in and around the injection site and 
quantitated by Nuance multispectral imaging system. Transduced HIV-1 
infected mice have significantly higher NF content staining than control groups; 
GFAP intensities were not significantly different amongst the groups (Fig. 1.5b, 
lower panel). Parallel analyses of synaptic markers that include microtubule 
associated protein 2 (MAP-2) and synaptophysin (SYN) failed to demonstrate 
changes as a result of therapy and when quantitated by similar multispectral 
imaging markers (data not shown). 
We next evaluated by real-time polymerase chain reaction (RT-PCR) the 
gene expression levels of sTNFR-Fc in the brain samples HIVE animals 
injected with transduced BMDM; pro-inflammatory cytokine and neurotrophic 
factor (GDNF and BDNF) expression levels were measured in brains of 
animals that received sTNFR-Fc or control vector containing BMDM. Notably, 
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expression of sTNFR-Fc was detected in the brains of animals that received 
transduced BMDM (Fig. 1.5c). No statistically significant differences in NOS2, 
IL-10, IL-1b, and TNF-α, BDNF and GDNF were noted between animals 
treated with transduced (TD) and non-transduced (NTD) BMDM (Fig. 1.5e). 
However, in these experiments measurement of pro- and anti- inflammatory 
and neurotrophic factors were also compared in brain tissues of HIVE controls 
(HIV-Ctl) with animals adoptively transferred with TD BMDM. Here, decreased 
expression of NOS2, IL-10, IL-1b and TNF-α shown in the TD animals 
compared to HIV-Ctl group (Fig. 1.5d). Adoptive transfer of macrophages in an 
HIVE experimental model might have by itself negative effects associated with 
additional influx of macrophages (with control vectors or non-transduced). 
Delivery of sTNFR by transduced BMDM at the initiation of inflammation 
showed positive anti-inflammatory effect. The reduction in microgliosis by 
sTNFR-GFP transduced BMDM and the induction of anti-inflammatory milieu 
might be contributing to the neuroprotective response with increased NF 
immunostaining around the injected area (Fig.1.5b). 
A similar approach has been applied in the PD study to deliver neurotropic 
and protective factors to attenuate neuroinflammatory processes linked to 
neuronal death [97]. Glial cell line–derived neurotrophic factor (GDNF) is the 
most potent survival factor for the nigrostriatal dopaminergic neurons that 
degenerate in PD [98, 99]. Current GDNF-based therapies have been 
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seriously hindered by the difficulty in delivering these therapies to the brain. 
Moreover, the progressive nature of PD requires continuous and sustained 
delivery of GDNF over months or years in order to maintain dopamine neuron 
survival and function. Conjugation of GDNF with other molecules enabling 
BBB penetration may partially overcome these difficulties and increase the 
feasibility of this approach for long-term sustained delivery of GDNF remains 
uncertain. Advancement in the development of cell-based gene therapy that 
can be applied systemically and achieve sustained release of moderate 
amounts of GDNF opened a new window (Fig. 1.6). Adoptive transfer of 
genetically modified macrophage expressing GDNF dramatically ameliorated 
neuroinflammation and reduced degeneration of the tyrosine hydroxylase 
positive (TH+) neurons of the substantia nigra and TH+ terminals in the striatum 
of the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) and the 
6-hydroxydopamine (6-OHDA) PD mice models [59, 97]. Genetically modified 
macrophages acting as carriages for GDNF were recruited into the substantia 
nigra of MPTP-treated mice, both the number of dopaminergic neurons and 
the level of dopamine were rescued in the striatum of MPTP-treated GDNF 
mice. In another study, exosomes released from GDNF-transfected 
macrophages resulted in the drastic increase of neuronal maturation with a 
pronounced outgrowth of axons and dendrites in PC12 neurons in vitro. This 
attributes to the potential mechanism of efficient interactions between 
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exosomal carriers and plasma membranes of dopaminergic neurons that 
facilitate GDNF binding to their receptors, resulting in the profound therapeutic 
effect. Nevertheless, due to the limited understanding, the mechanism 
responsible for the therapeutic effects of cell-based GDNF delivery remains 
inconclusive. Recently the hypothesis that growth factors could effectively 
protect from endoplasmic reticulum stress, augment autophagy and brake or 
significantly reduce speed of misfolded proteins accumulation in PD, HD, ALS 
and AD was reviewed [100, 101]. A comprehensive examination and detailed 
understanding of the mechanisms would be of great value in designing 
strategies for cell-mediated drug delivery.  
As inflammation has been implicated as a critical mechanism in AD 
pathogenesis, suppression of microglial activation and subsequent 
neuroinflammation was investigated employing several anti-inflammatory 
drugs in trial, including natural nonsteroidal anti-inflammatory drugs (NSAIDs), 
polyphenols and new drugs synthesized based on multi-target directed ligand 
(MTDL) design [102]. TNF-alpha inhibitor administered perispinally in patients 
with mild-to-severe AD showed promise as potential treatment approach [103]. 
Adjunctive therapies targeting multiple factors in AD processes might be the 






Figure 1.1. Neuroimmunological mechanisms for HAND. A vigorous innate 
immune response occurs as a direct consequence of brain mononuclear 
phagocytes (perivascular macrophages, microglia) infection that drives a 
pro-inflammatory and virotoxin-associated neurotoxic response. This is 
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perpetuated by an autonomous amplification of cytokine activities like TNF-α 
and by a persistent chemotaxis of HIV-1 infected macrophages from periphery 
in the setting of a failure of immune responses or an absence of antiretroviral 
therapy. Meanwhile HIV-1 infected macrophages interrupt astroglial function 
and integrity by pro-inflammatory mediators, compromising the metabolic 
function and homeostasis of the CNS. Neuronal loss in HIV-1 encephalitis is 
associated with synaptic and dendritic damage. Overt synaptic loss is in turn 




Figure 1.2. Macrophage-based gene and immune modulatory therapies. The 
chemokine gradient in diseased brain drives transduced macrophage 
constitutively expressing sTNFR:Fc to the inflammatory site. Local release of 
sTNFR:Fc reverses the pro-inflammatory microenvironment and blocks a cycle 
of autocrine and paracrine cytokines produced by sequestering the major 
pro-inflammatory mediator TNF-α.  
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Figure 1.3. Combination of adjunctive and antiretroviral treatments for HAND. 
Delivery of nanoART using macrophage as carriage serves to control HIV-1 
replication in the brain by bringing antiretroviral drugs to local sites of viral 
growth. The long-acting nanoformulated-antiretroviral medicines are in the 
same subcellular viral compartment within multivesicular bodies (MVBs). This 
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serves to reduce viral loads and numbers of peripheral HIV-1 infected CD4+ 
T-cells. Drug levels are sustained in reservoirs of viral infection. Upon the 
suppression of persistent inflammation and clearance of viral brain reservoirs, 





















Figure 1.4. Adoptive transplantation of sTNFR-GFP transduced BMDM into 
HIVE mice. BMDM transduced with the sTNFR-GFP at day 7 in vitro were 
shown positive for enhanced GFP expression and started to exhibit 
macrophage-like branching appearance. One of three representative 
experiments is shown (A). Transduction efficiency measured by flow cytometry 
ten days post transduction demonstrated more than 45% transduced BMDM 
were GFP+, one of three representative experiments is shown (B). 
Four-week-old female NSG mice were stereotactically injected intracranially 
into the caudate putamen with HIV-1ADA–infected MDM (2 × 105 cells in 5µl) 
after 1 d of viral infection and referred to as HIVE mice (C). These mice were 
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subsequently transplanted with 4×106 transduced (TD, n=12) or 
non-transduced (NTD, n=10) BMDMs in 200 µl PBS through tail vein. HIVE 
controls (HIV-Ctl) were injected with same volume of PBS (n=8); SHAM 
controls were only intracranially injected with 5 µl PBS (n=6). The mouse 





























Figure 1.5. Delivery of sTNFR by transduced BMDM demonstrated an 
anti-inflammatory effect in an HIVE model. Immunohistochemical staining of 
HIV p24 protein identified HIV-1 infected human MDM at injection site. 
Evaluation of astrogliosis and microgliosis by GFAP and Iba-1 staining 
revealed adoptive transplantation of sTNFr:Fc-GFP transduced BMDM 
attenuated the microgliosis surrounding injection site compared to 
transplantation of NTD cells. But no apparent reduction of astrogliosis was 
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observed (A). GFAP/Neurofilament staining in the injection site were analyzed 
by Nuance multispectral imaging system (20X objective). The representative 
images are shown. Transduced group have significantly higher content of NF 
(green) staining in comparison with other groups. However, the difference in 
the intensity of GFAP was not statistically significant among groups (B). The 
expression of genes encoding TNFR:Fc, NOS2, IL1-β, TNF-α , NOS2, BDNF, 
and GDNF in brain subregions containing injection site were measured by 
real-time RT-PCR using SYBR green system and specific primers. n=5 in TD 
group, n=6 in NTD group, n=3 in HIV Ctl group. The expression of TNFR:Fc is 
more than two-fold higher in TD than in NTD brain (C). The expression of 
inflammatory cytokines including NOS2, IL-10, IL-1β, TNF-α and neurotrophic 
factors like BDNF and GDNF, is lower in TD than they are in HIV-Ctl brain (D). 
No significant differences in expression in TD group when compared to NTD 
group were found (E). For multispectral image quantifications, images were 
converted to 12 bit grayscale and quantified using ImagePro plus software. 
There are 3 animals in each group, and 4 sections of selected regions from 
each animal were analyzed and quantified. Each bar represented as mean ± 
SEM, P values were obtained using one way ANOVA test, * p < 0.05. 
Antibodies used include mouse anti-Neurofilament (1:200, Clone 2F11, Dako, 
CA), polyclonal rabbit anti-GFAP (1:1000, Dako, CA), and rabbit anti- Iba1 
(1:500, Wako, VA). For real-time RT-PCR, Ct values of each target gene were 
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normalized to values for GAPDH in each sample. To calculate relative 
amounts mRNA, the average Ct values were subtracted from GAPDH values 
for each target gene to provide changes in Ct value. Fold Change in 
expression was calculated as log2 relative units. Multiple t tests using 
Holm-Sidak method were applied for statistical analysis. Each bar represent 


















Figure 1.6. Common mechanism of neurodegenerative pathology mediated 
by microglia and astrocyte activation, and reversal of neuronal dropout by 
introducing neurotrophic factors by transduced macrophages. Activated 
microglia undergo a series of morphological, molecular and secretory changes 
in the presence of abnormal proteins generated by neurons (a-synuclein, 
amyloid etc.) that lead to a pro-inflammatory microenvironment in the CNS, 
and, as results progressively increasing build-up of misfolded proteins. These 
include the induction pro-inflammatory mediators such as IFN-g, NF-α and 
IL-1β speeding the neuronal dysfunction and degeneration. The interplay 
between microglia and astrocytes further impairs the astrocytes capability of 
maintaining homeostasis and nourishing neurons with neurotrophic factors like 
GDNF, BDNF, and NGF (A). Adoptive transfer of genetically modified 
macrophage expressing neurotrophic factors dramatically ameliorated 
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neuroinflammation and reduced degeneration of neurons in rodent models of 
AD and PD. Uptake of exosomes containing neurotrophic factors released 
from transduced macrophages resulted in a reduction of misfolded protein 
production via autophagy and should significantly delay their accumulation (B). 
The efficient interactions between exosomal carriers and plasma membranes 
of neurons that facilitate growth factor binding to their receptors may contribute 

























CHAPTER - 2 













Since the emergence of HIV in humans in the 1980s, tremendous successes 
have been achieved in restraining an infection, once considered fatal, into a 
controllable illness with compliant affected individuals surviving for decades 
with improved quality of life. During this journey, animal models offered 
obvious advantages in the study of HIV/AIDS, allowing for a more invasive 
investigation of the pathogenesis and for preclinical testing of drugs and 
vaccines. Advances in humanized mouse models, non-human primate models, 
and transgenic rodents, as well as recombinant challenge viruses have greatly 
empower researchers in dissecting the pathological mechanisms, developing 
novel antiretroviral therapies and vaccines, for the prevention and eradication 
of HIV-infection. 
As introduced in the previous chapter, the prevalence of milder forms of 
HAND (e.g., asymptomatic neurocognitive impairment) have increased from 
approximately 25 to 33%, despite of the extensive application of potent 
antiretroviral therapy [6]. New challenges appear as to uncovering the 
mechanisms by which the milder neurocognitive impairment persist in 
HIV-infected individual regardless of effective suppression of plasma viral load.  
Interestingly, the pathological presentations of patients with milder 
neurocognitive impairment also tend to be subtle, instead of dramatic changes 
like infiltration of lymphocytes and virus that often observed in encephalitic 
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patients. Therefore, more rigorous investigations into the underlying 
pathophysiological mechanisms need to be carried out. Animal models will 
continue to enable the study of HAND and testing of new therapeutic 
approaches to combat them. Here we review the contributions of different 
models to the understanding of HIV neuropathogenesis. While addressing the 
limitations of currently available models, we propose a new mouse model that 
readily reflects HIV neuropathogenesis in the era of cART. 
 
2.2 Brain cells critical for HIV neuropathogenesis 
In the chapter 1, we have reviewed the mechanisms involved in neuronal injury 
during brain infection with HIV. Needless to say, damage to neurons would 
eventually lead to impairment in neurocognitive performance. Among other 
cellular components contributing the development of HAND, brain 
macrophages, microglia, and astrocytes are the key players.  
 
2.2.1 Brain macrophages and microglia  
The key cells that support productive HIV infection in the brain are 
macrophages and microglia [8, 104]. However, distinctive from a traditional 
view that microglia originated from bone marrow-derived monocytes that 
circulate in the blood and enter the brain in non-pathological conditions and 
during inflammation, recent population-based gene expression assays and 
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fate-mapping studies revealed that microglia radically differ from brain 
macrophages residing in perivascular and meningeal spaces in origins, fates, 
and functions [105, 106].   Microglia derived from primitive hematopoiesis 
that is spatiotemporally distinct from definitive hematopoiesis in fetal liver and 
bone marrow, then migrate into neuroectoderm and distribute throughout the 
CNS in later embryonic, fetal, and postnatal stages [107, 108]. While this topic 
is out of the scope of this review, the distinction between microglia and brain 
macrophages becomes extremely important when it comes to the questions of 
repopulating mouse brains with human MPs-which progenitor population 
should be chosen for the transplantation? Brain macrophages seem to be a 
major target for the dissemination of HIV infection to the brain from the 
periphery. Interestingly, it has been shown that HIV-infected monocytes can 
cross the BBB more readily than uninfected monocytes [109]. These findings 
are informative for the application of humanized mouse models to recapitulate 
MP mediated viral entry and neuroinflammation [110]. Meanwhile, microglia 
are equally important target of HIV infection, and are recognized as a potential 
viral reservoir in the CNS, posing a barrier for viral eradication. However, the 
establishment of a rodent model carrying human microglia has been hindered 
due to an insufficiency of knowledge in the precise identity of microglial 
precursors and an absence of optimal mouse platforms to support the survival 
and development of human microglia.  
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2.2.2 Astrocytes  
Perivascular astrocytes are another cell receiving increasing attention as an 
important reservoir for HIV [37, 111]. Previous studies showed that, in 
individuals with HAND, as many as 19% of the perivascular astrocytes are 
infected with HIV [111]. However, it is inaccurate to state that the HIV-1 DNA 
detected in 3-19% astrocytes from autopsy brain tissues were 
replication-competent proviral DNA. Due to the ex-vivo nature [111, 112], the 
original studies were not able to conclude if the nearly 20% astrocytes are true 
infections or restricted infections.  According to decades of research, infection 
of astrocytes by HIV is highly restricted [113].  On one hand, the restricted 
infections stem from insufficient receptor-medicated viral entry due to a lack of 
necessary receptors. On the other hand, restrictions were also noted in viral 
replication and assembly, which are majorly induced by type 1 interferon 
receptor activation and signaling. However, astrocyte adsorption and uptake of 
cell-free virus particles via endocytosis-mediated viral entry would lead to 
detection of infectious viral nucleic acids in cultures or ex vivo analyzed 
astrocytes [114, 115]. Additionally, astrocyte engulfment of HIV-1 infected 
permissive cells like macrophages and lymphocytes or their subcellular 
components would also lead to detection of astrocyte-associated viral proteins 
and nucleic acids that could be mistaken for infection [116].  Therefore, it is 
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very imprudent to equate detection of viral materials to the productive infection 
of astrocytes.  
But controversy still remains regarding whether astrocytes would be likely 
to serve as viral reservoirs. Also, the possibility cannot be excluded that 
astrocytes in situ exposed to the neural tissue environment may be induced to 
express CD4 and CCR5, and therefore be susceptible to HIV-1 infection. 
Because astrocytes outnumber neurons by 10:1, this could represent a large 
amount of infection in the brain, which was previously under-recognized.  
 
2.3 Non-human primate model  
As non-natural SIV hosts, Asian macaques have become the most common 
and widely accepted models for HIV/AIDS pathogenesis and latency. Studies 
on HIV-neuropathogenesis have been extensively paralleled in SIV-infected 
rhesus macaque models. However, disease progresses more rapidly in 
SIV-infected macaques than in HIV-infected humans, typically 1-2 years to 
AIDS in SIV-infected animals compared to 8-10 years in humans, if not 
receiving antiretroviral therapies [117]. Although later stages of the disease 
have been investigated in detail where pathology of encephalitis is apparent as 
a result of the activation of virus-infected mononuclear phagocytes and 
lymphocyte infiltration, the pathophysiological alterations at early stages after 
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acute infection remain largely unknown in this model.  Additionally, it is costly 
to work with these large animal models. 
 
2.4 HIV transgenic rodent model 
The cost of working with non-human primate model restricts them from being 
broadly used. To this end, a cost-effective small animal model is more 
practically acceptable. Since the well-established methods for manipulating 
the mouse and rat genome provided researchers a larger extent of flexibility in 
dissecting the roles of specific factors in a pathological process, rodent models 
play increasingly important role in HAND research. Because HIV is not 
infectious to rodents, efforts have been made using genetic techniques to 
circumvent the species-specificity of the virus to create rodents to mimic 
human pathology.  
One approach was to express human receptor and co-receptors 
necessary for viral entry, such as CD4, CCR5, and CXCR4, on the surface of 
murine cells [118]. This is based on the rationale that the restriction on viral 
entry imposed by species-specific receptors prevents murine cells from being 
effective infected by HIV. This theoretic cornerstone was soon proved unsound.  
Although these mouse models support viral entry, the primary barrier to HIV 
infectivity in mouse is that the cells are unable to support HIV replication. This 
is due to the intrinsic restrictions imposed by a series of restrictive factors, 
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such as TRIM5a, APOBEC3, SAMHD, that prevent viral integration into the 
mouse genome and subsequent viral production [119, 120]. Alternative efforts 
made on engineering viral structures, for instance replacing gp120 to a murine 
cells tropic gp80, also failed to establish HIV replication and progression [121].  
Additionally, models selectively expressing viral accessary or regulatory 
proteins in specific type of cells have also been broadly applied to investigate 
the effect of these proteins on neuroinflammation [122, 123].  This approach 
is to genetically engineer rodents to express non-infectious provirus, with 
deletion of gag and pol genes. The transgenic rodent models do not focus on 
the infection, but on the effect of accessory and regulatory viral proteins in 
neuroinflammation. As reviewed in the previous chapter, these proteins, 
including gp120, Nef and Tat can exert neurotoxicity by direct action on 
neurons and by producing inflammation via inducing cytokine production in the 
periphery and CNS [124]. Although infection results in an adaptive 
inflammatory response, inflammation can also emerge independent of 
infection, and chronic inflammation can lead to neurodegenerative disorders 
[125]. HIV-1 transgenic rats showed significantly higher mRNA and protein 
levels of the inflammatory cytokines, IL-1β and TNF-α, as well as a decrease in 
the neuroprotective brain-derived neurotrophic factor (BDNF), among other 
changes in regulatory factors and signaling [126]. Similarly, another study 
determined that pro-inflammatory cytokines, such as IFN-γ, TNF-α, and IL-1β, 
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are up-regulated in the HIV-1 transgenic rat, which is in part responsible for the 
neurodegeneration seen in HIV-infected individuals [127]. 
Evidence from studies employing different experimental strategies strongly 
support the hypothesis that viral proteins produce toxic effects that cause 
neuroinflammation and neurological dysfunction. The viral protein gp120 binds 
to the chemokine receptor, CXCR4, an HIV-1 co-receptor involved in AIDS, 
that is also expressed in neural progenitor cells to guide brain development 
[128]. Gp120 stimulates CXCR4 and activates pro-apoptotic pathways in 
human neuroblastoma cells [129]. Gp120 also induces apoptosis through its 
interaction with the CCR5 receptor [130]. The transgenic mice that contain 
astrocytes expressing gp120 under the control of the promoter of glial fibrillary 
acidic protein (GFAP) developed CNS damage consistent with 
HIV-1-associated neuropathology [12].  
The supplementary HIV-1 proteins also produce neurotoxicity. Tat is one 
of the proteins produced by HIV following early infection. Even in the absence 
of viral replication, a large amount of Tat protein can be produced and secreted. 
Transgenic mouse lines that express Tat protein using GFAP promoter in 
either constitutive or inducible manners were created to understand the 
contribution of Tat protein to the HIV neuropathogenesis [131, 132]. Similar to 
gp120 transgenic animals, Tat transgenic mice demonstrated 
neuropathological changes. Subsequent studies linked the neurotoxicity of Tat 
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to its pro-apoptotic effect via excessively stimulating NMDA receptors, and by 
interacting with the low-density lipoprotein (LDL) receptor gene family 
expressed in neurons and astrocytes [133, 134]. Changes in neuronal circuitry 
also occur in response to the presence of Tat and, as do deficits in learning 
and memory following exogenous Tat as well as endogenously expressed Tat 
[135]. Other viral proteins, such as Nef Vpr and Vpu, have also been 
demonstrated with neurotoxic effects, producing inflammatory cytokines, and 
affecting CNS function and behavior, including memory performance of 
standard learning tasks [136-138] 
  While the transgenic rodent models are suitable for elucidating the 
mechanisms underlying impairment in neurocognitive function caused by the 
accumulation of viral gene products, they are not helpful for examining the 
initial infection with HIV and the progression of the disease from a perspective 
that the virus interacts with immune and neural networks as an integral entity. 
Another caveat is that they are not suitable for studying the impact of cART on 
viral replication, though many adjunctive therapeutic approaches have been 
developed and tested using such platforms. Moreover, the significance of 
many studies using transgenic mouse models to examine the impairment in 
cognition and memory are undermined by the fact that most these behaviors 
studies were initially designed for rat and interspecies differences do exist 
regarding spacial learning and task memory [139]. 
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2.5 Humanized model 
Generally, humanized mouse refers to a mouse carrying functioning human 
cells, tissues, and organs. However, with our focus on models for studying HIV 
neuropathogenesis, we limit the scope of this review to mouse models 
reconstituted with human immune and nervous systems and their applications 
in understanding pathological processes and in developing therapeutics.    
 
2.5.1 The HIV encephalitis mouse model 
Historically, HIV-encephalitis characterized by infiltration of infected MPs and 
active viral replication in the brain, correlates to a rapid decline in 
neurocognitive functions in the pre-cART era [140]. Therefore, the first 
attempts to reflect the pathogenesis of HIV encephalitis (HIVE) was performed 
by injecting MPs that are infected with a macrophage-tropic strain of HIV-1 
(HIV-1ADA) into the brain of immunodeficient mice [141]. These infected cells 
were stereotaxically injected into the basal ganglia, putamen or cortex [142]. 
Following implantation, these mice exhibited histopathological features 
paralleling those observed in human HIVE, including expression of HIV p24 
antigen in the infected macrophages, the formation of multinucleated giant 
cells, astrocytosis, microglial activation and neuronal cell death. Subsequent 
efforts were made to assess neuronal function in the HIVE model using a 
range of behavioral and functional tests. Mice injected with MDMs developed 
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cognitive impairments and associated synaptic dysfunctions [143-145]. This 
mouse model has also been used extensively for evaluating new antiretroviral 
and adjunctive therapeutics as well as delivery systems for HIVE. Various 
antiretroviral strategies were assessed to maximize drug-brain delivery and to 
reduce HIV-1 replication within the brain in HIVE mice [92, 146, 147]. As 
previously mentioned, because activation of MPs by HIV infection can further 
induced an autonomously amplified inflammation that 
affects synaptic plasticity and neuronal development in HIV-infected 
individuals, much research effort has been focused on the discovery and 
design of neuroprotective compounds as adjunctive therapies to cART. The 
HIVE mouse model has also been proved to be useful for screening potential 
neuroprotective compounds [60, 148, 149].   
Despite the enormous contributions of HIVE model to the study of 
neuroAIDS, it seems unable to reflect the rapidly evolving face of HIV 
neuropathogenesis in the era of cART, since the noticeable pathology of HIV 
encephalitis becomes rare in the well-treated patients. Moreover, traumatic 
injury resulting from stereotaxic injection may confound the traumatic brain 
injury with infection-induced injury, making it hard to interpret the experimental 
results. Finally, the average 2-5 weeks period of active infection and 
inflammatory responses makes this model unable to mimic chronic infection.  
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2.5.2 Human immune system reconstituted model 
Previous models cannot fulfill the goal of establishing a model system that can 
sustain long-term chronic HIV infection to investigate the ongoing interactions 
of peripheral infections to brain immune cell ingress, neuroinflammation and 
resulting neurodegeneration.  This was made possible by the development of 
mouse strains with severe defects in both innate and adaptive immunity. 
These include the partial deletion of common cytokine receptor γ chain (γc–/–, 
or interleukin-2 receptor γc) on a NOD/ShiJic-scid (NOG) mouse 
background and a complete deletion of γcnull on NOD/LtSz-scid (NSG) mouse, 
as well as the BALB/cRag2–/–γc–/– (BRG) mouse.  Humanized mouse models 
have been established in the NOG, NSG, and BRG mice by intrahepatic 
administration of CD34+ hematopoietic stem cells (HSC model) into newborn 
pups, or by surgical transplantation of human fetal liver and thymus tissue 
fragments followed by intravenous injection of human fetal liver-derived 
CD34+ HSC (BLT model). Although the BLT mouse model has been 
extensively used to investigate important aspects of HIV-associated pathology, 
transmission, prevention, and more recently HIV persistence [150-152], this 
model has not been used for studies of HIV infection of the CNS. Therefore, 
we will only review the applications of the HSC model in the studies of 
NeuroAIDS in the following paragraphs. 
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The long-term immune reconstitution of NOG/NSG mice by human HSCs 
provides a new approach to study HAND. The major characteristics of chimeric 
animals are stable human hematopoiesis in mouse bone marrow, occupancy 
of the murine thymus with human thymocytes and their maturation into T 
cell subsets, complete reconstitution of murine peripheral lymphoid organs 
including lymph nodes and spleen, as well as gut-associated lymphoid tissue 
(GALT), and the infiltration of human macrophages throughout brain 
parenchyma, the meningeal and perivascular spaces [153-156]. These human 
immune system reconstituted mice support chronic HIV-1 replication and 
recapitulate the course of viral replication, with loss of CD4+ T cells and the 
development of HIV-1-specific cellular and humoral immune responses [157, 
158]. It was also found systemic HIV infection accelerated the entry of 
peripheral human immune cells into the brain [154]. Viruses were thereby 
disseminated throughout the brain as the peripheral infected cells infiltrated. 
Astrogliosis and microglial activation, as well as neuronal injury, were 
commonly seen, and neurodegeneration was found to correlate with peripheral 
viral load and CD4+ cell depletion [53]. The development of meningitis, and 
more rarely meningoencephalitis, was observed [154]. These findings, taken 
together, suggested natural HIV-1 progression within the CNS of human 
immune system reconstituted mice.  
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Considerable studies have been carried out on humanized mouse models 
to test the efficacy and safety of cART and neutralizing antibodies, given its 
ability to sustain a long-term viral replication [159, 160]. Nevertheless, there 
are very few reports on the effects of these therapies on the neuropathology of 
HIV infected mice. It is probably due to the low tissue distribution of regular 
cART to the brain [161]. Recently, one study demonstrated the long-acting 
nanoART elicited neuroprotective responses with remarkable reversal of 
synaptic injury when compared to untreated virus-infected animals [162], 
suggesting such long-acting nanoART has improved brain delivery, sustained 
and targeted efficacy and with limited systemic toxicities. Such findings also 
strongly suggest that the humanized mouse model is likely to be a valuable 
tool for evaluating the targeting delivery and efficacy of 
long-acting antiretroviral drugs. 
 
2.6 Humanization of mouse brain and future directions 
Although the HIV-infected humanized mouse models have been characterized 
extensively for their ability to recapitulate the human immune response against 
HIV, and been applied widely to test the efficacy of therapeutic approaches, 
they are insufficient to assess HIV-associated neuropathology and related 
neurocognitive dysfunctions. In 2012, Laura B. Jaeger and Avindra Nath 
discussed the possibility of establishing a new mouse models with combined 
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human immune system and brain cells (primarily microglia and astrocytes) 
reconstitution to study HIV neuropathogenesis [163].  The advantage of such 
a chimeric mouse model is that both the transplanted human lymphoid and 
brain tissue will be permissive to HIV infection, thereby enable the study of 
neuropathological mechanisms that contribute to the development of HAND in 
one physiological setting. Since microglia and astrocytes are considered to be 
potential viral reservoirs in the CNS, such model will also be valuable in 
investigating viral reservoirs and in developing strategies for eradication. But 
due to time limits, this review only summarized studies engaged in 
humanization of mouse brains published before 2012, including those studies 
have successfully implanted different brain cells into the mouse brain, such as 
neurons, oligodenrocytes, and neuroprogenitors cells, but not astrocytes and 
microglia [164-167]. However, recent studies demonstrated the engraftment of 
mouse brain with A2B5+/PSNCAM- glial progenitors generating a chimeric 
mouse brain primarily reconstituted with human astrocytes [168, 169]. 
Previous work also showed transplantation of human neural progenitor cells 
(NPC) in an ischemic or traumatically injured rat brain are capable of 
differentiating into cells bearing neuronal markers with only limited numbers of 
GFAP+ cells at the injured brain margins [170]. From these studies, it has been 
shown that early transplantation is essential for achieving maximum migration 
of human glial cells in the mouse brain [171, 172]. These studies, taken 
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together, confirmed the feasibility of establishing a human immune 
system-glial dual reconstituted mouse model. 
 Regarding the reconstitution of human microglia, which is another player in 
HIV infection of the CNS and an important viral reservoirs, continued efforts 
need to be made to identify the human microglial progenitors during primitive 
hematopoiesis, and to generate a mouse brain microenvironment permissive 
to human microglial survival and development. As reviewed in the previous 
paragraph, recent fate-mapping and gene expression profiling studies 
revealed that microglia originate from primitive stem cells in the yolk sac at the 
early stage of embryogenesis, and not from hematopoietic stem cells in the 
bone marrow, nor from neuroectoderm which gives rise to neurons, astrocytes 
and oliodendrocytes as well as ependymal cells [105, 108, 173]. They then 
migrate into to neuroectoderm and distribute throughout the CNS in the later 
embryonic, fetal, and postnatal stages. During the development of microglia, 
colony-stimulating factor-1 (CSF1) was initially found to provide survival signal 
for developing microglia. However, later it was found microglia are more 
profoundly affected by the absence of CSF-1 receptor (CSF1R) than by CSF1. 
A second CSF1R ligand, interleukin-34 (IL-34) was identified later, and has 
been shown to be highly expressed by neurons and play a critical role in 
microglial survival and differentiation [174, 175]. These findings are informative 
for the future efforts to genetically engineer a mouse strain expressing IL-34 in 
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the brain to provide a permissive microenvironment for human microglia 
engraftment. 
Finally, these immune-CNS dual reconstituted models would be remarkably 
useful for detection of biomarkers that could be used to assess 
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Studies of innate glial cell responses after progressive human 
immunodeficiency virus type one (HIV-1) infection are hindered due to the 
paucity of relevant small-animal models of human disease. To overcome this 
limitation, a mouse model with dual humanized brain and immune system was 
created. We transplanted newborn NSG mice both with human neuroglial 
progenitor cells (NPCs) and hematopoietic stem cells (HSCs). This 
experimental approach resulted in human astrocyte and oligodendrocyte 
repopulation in anatomically symmetrical white matter and periventricular 
mouse brain regions. RNA sequencing was applied to examine the influence of 
human cells engraftment on the mouse transcriptional profile in selected brain 
regions. Glial humanization of mouse brain with a human peripheral immune 
system induced modest, yet extensive, transcriptional changes associated 
with multiple biological processes, including synaptic transportation, 
angiogenesis, axon growth, ion channel activities. 
 
3.2 Introduction 
Despite sustained investigation of the pathophysiological mechanisms of 
HAND, virus-induced neuroimmune communications are not well understood 
[176, 177]. As the virus cannot infect rodent cells, disease conditions that 
cause immune, glial, and neural cell dysfunctions cannot be mirrored in any 
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small animal. Transgenic mice containing the whole viral genome or 
individually expressed proteins and the brains of animals injected with viral 
proteins or human infected cells reflect only disease components [178]. 
Lentiviral infections of non-human primates, cats, and ungulates do replicate 
HIV nervous system comorbidities [179], but show broad gaps in mirroring 
natural infectious processes [180]. This can also be argued with mice who 
possess a self-sustainable humanized immune system. These humanized 
animals are susceptible to HIV infection and support persistent replication of 
virus, but resultant structural and functional changes to the brain are limited 
[181-183]. The absence of human glial cells and differences in responses to 
the virus, between species, combined with functional system complexities limit 
mechanistic studies [184].  
 As the most abundant cell types in the human central nervous system, 
astrocytes and oligodendrocytes, have pivotal roles in brain homeostasis and 
metabolism. Astrocytes are limited in their susceptibility to HIV infection [185, 
186] and they are abortively infected [187]. In contrast, oligodendrocytes, 
which produce myelin, are not vulnerable to HIV infection. During disease, 
communication between astrocytes and infected mononuclear phagocytes 
(MP; monocyte macrophages and microglia) herald changes in the brain’s 
pro-inflammatory microenvironment. Amongst each of these cells, except for 
MP and CD4 T cells, multiple intracellular restrictions exist. For example, viral 
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receptors, absent on the cell surface of astrocytes, are operative on MP, which 
leads to differential abilities of the virus to complete its life cycle [188, 189]. 
The interactions between lymphocytes and monocytes that traffic into the 
nervous system drive glial activation during progressive viral infection [190]. 
Thus, if a disease model can accurately replicate the complex features of an 
infection of the nervous system, in a single physiological system, it must 
contain both a human immune and glial elements [178]. To such ends, we 
established a dual reconstituted mouse model that incorporates human 
lymphocytes, monocytes and glia. Glial humanization of mouse brain with a 
human peripheral immune system induced modest yet extensive 
transcriptional changes associated with multiple biological processes. The 
importance of this model is underscored by ability to study specific glial 
transcriptional signatures that closely mirror human disease [176]. 
 
3.3 Results  
3.3.1 Human brain cell transplantation 
Mice were reconstituted with human hematolymphoid tissues and glial cells. 
Newborn irradiated NSG mice were transplanted intracranially with human 
NPCs and intrahepatically with cluster of differentiation 34 (CD34)+ HSC from 
the same donor (Fig. 3.1A, Table 3.3). NPCs were isolated from fetal human 
brains to generate neurospheres, from which single cell suspension was 
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prepared and transplanted at 105 cells per mouse (Fig 3.1B). The lineage 
potential of the NPCs were investigated in short-term cultures. Mixtures of 
neural lineage cells arising from parental progenitors included glial fibrillary 
acidic protein (GFAP)/microtubule-associated protein (MAP) glial progenitors, 
nestin/GFAP neural progenitors with radial glia characteristics, glutamic acid 
decarboxylase 67 (GAD67) and class III β-tubulin (Tuj-1)+ neuronal lineage 
cells (Fig 3.1C). These data indicated that the NPCs derived from fetal brains 
retained multi-lineage competence.  
Glial cells were stimulated and neuronal differentiation limited by exposure 
of NPCs to escalating concentrations of fibroblast growth factor prior to 
intraventricular cell transplantation. The fate and distribution of the human 
NPCs in mouse brain were then evaluated at 6 months of age (Fig. 3.2). 
Human glial were found equally across both hemispheres with distributions in 
the corpus callosum (CC), striatum (Str), cerebellum (CB) and periventricular 
areas (Fig. 3.2 A). A large proportion of the human cells in mouse brains were 
GFAP positive with typical astrocyte morphology based on size and process. 
Human astrocytes commonly replaced their murine counterparts with nearly 
70–80% occupancy. This was seen in fields of view that included the CC and 
Str. There was limited occupancy of human astrocytes in the frontal cortex 
(FC) and CB (Fig 3.2 C). Surprisingly, nearly 40% of human astrocytes in the 
	 60 
CC and 20–30% in the hippocampus (Hip) and Str were Olig2+, an 
oligodendrocyte-identifying marker (Fig 3.2 B and D). 
 
3.3.2 Peripheral hematolymphoid humanization 
A human peripheral hemato-lymphoid system was established in the NSG 
mice (Fig 3.3, Table 3.3) [182]. Flow cytometric analyses of the peripheral 
blood of humanized mice at 24 weeks of age showed that among human 
CD45+ cells, B (CD19+) and T lymphocytes (CD3+) were present (Fig 3.3 A). 
CD4+ T lymphocyte population was four times that of CD8+ cytotoxic T cells 
(Fig 3.3 B). The CD14+ monocyte population was approximately 1% of the total 
CD45+ cells. Human hematopoiesis was sustained in the bone marrow as 
seen by the presence of CD34+ HSC and CD33+ myeloid lineage precursor 
cells [191, 192]. In the brain, human peripheral blood leukocytes infiltrated the 
meningeal and perivascular spaces, the olfactory bulb and the cortex. The 
majority of HLA-DR cells were located in the meningeal space, with fewer 
numbers in the perivascular space and brain parenchyma (Fig 3.3 C and D). 
Among these, the majority were CD163+ macrophages, and some showed 
branching appearances. Less than 20% of HLA-DR cells were CD4+, and 9% 
were CD8+ T lymphocytes (Fig 3.3 C and E). 
 
3.3.3 Transcriptional changes in the humanized mouse brain 
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To assess the biological outcomes of peripheral immune and brain 
humanization, we applied deep sequencing to assess transcriptional profiles 
seen as a consequence of glia-immune crosstalk. We selected three infected 
animals with similar patterns of human immune cell repopulation, astrocyte 
distribution and peripheral viral loads for study. Three equivalent aged NSG 
uninfected mice served as controls (Fig 4.2 A). Hip and CC repopulated by 
human glial cells were dissected for sequencing (Fig 4.2 C). All sequenced 
reads (~100 bp length) were aligned to the mouse database (University of 
California Santa Cruz Genome Browser database, GRCm38/mm10). The 
experiment was designed to search for differentially expressed mouse 
transcripts as a result of human cell engraftment and HIV-1-infection. 
Subsequently, the reads unmapped to the mouse genome were re-aligned to 
the human genome (GRCh38/hg19) to find human specific transcriptional 
changes. The overall mapped mm10 reads average ratio was 92% for all 9 Hip 
samples and 94% for all 9 CC samples (Table 3.2).  
 
3.3.4 Region-specific alterations of mouse transcriptom by engrafted 
human glial cells 
We used GeneCards® integrative database to obtain categorized results for 
differentially expressed mouse genes. This was done to identify Gene 
Ontology (GO) gene sets related to mouse brain humanization. The obtained 
	 62 
information about the biological roles of the genes of interest we summarized 
in Fig 3.4. Glial humanization of mouse brain with a human peripheral immune 
system induced modest, yet extensive, transcriptional changes associated 
with multiple biological processes, including synaptic transportation (C1QL2), 
regulation of neural progenitor cell proliferation (RASL10A), angiogenesis 
(DCN, ENPP2), axon growth (SERPINI1), ion channel activities (SLC8A2), 
learning and memory, aging (Fig 3.4). 
 
3.4 Discussion  
We created a unique mouse model that contains both a human immune 
system and human glial cells in the brain, which will allow us to investigate the 
neural-immune interactions during progressive HIV infection and the reservoirs 
in the CNS.  
We confirmed that NPC can differentiate into multiple neural lineages, 
including neurons, astrocytes, and oligodendrocytes [193]. Previous work 
demonstrated that transplantation of human neurosphere-derived NPC can 
occur in a living mouse with viable human-derived neurons and glial cells [194, 
195]. Moreover, transplantation of hu-NPC in an ischemic or traumatically 
injured rat brain are capable of differentiating into cells bearing neuronal 
markers with only limited numbers of astrocytes present at the injured brain 
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margins [170]. Nonetheless, early transplantation is essential to optimize 
migration responses of human glia in mouse brains [171, 172].  
 We showed that human NPC transplanted into immunodeficient NSG mice 
at an early postnatal age (P1) demonstrated a broad glial distribution pattern. 
By 6 months of age, a large number of human astrocytes repopulated multiple 
regions along whiter matter tracts. Surprisingly, these cells derived from 
hu-NPC, readily replaced their murine counterparts. This was seen in selected 
regions such as CC and striatum (Fig 3.2 A and B). We also found a 
considerable number of human cells positive for Olig2 (Fig 3.2 C and D), a 
determining factor for oligodendrocyte differentiation. Glial-biased 
differentiation seen in our humanized brains can be explained in two ways. 
The in situ fate of NPC is restricted by the local white-matter environment 
[196]. The molecular signals in the recipient white matter may provide the 
migration route for human cells and facilitate a glia-oriented fate, possibly 
without any exogenous influence. Second, a fundamental feature of brain 
development is that neurons can be generated before glia [197]. Expansion of 
these neural progenitor cells in the presence of fibroblast growth factor (FGF) 
and leukemia inhibitory factor (LIF) may drive these cells toward a stage where 
glial bias is increased with concomitant loss of neurogenic potential [198]. 
 Interestingly, human glial engraftment induced a broad range of changes 
in the mouse transcriptional profile. The mouse genes relate to biological 
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process including synaptic transportation, angiogenesis, axon growth, ion 
transport, learning or memory were found modestly up-regulated (Fig 3.4). 
Although it is hard to precisely predict the consequence of human glia 
engraftment on mouse brain structure and neurological function at this stage, 
previous studies indeed demonstrated human astrocytes possess higher 
structural complexity and functional capacity than their murine counterparts 
[199], and engraftment of human glia differentially enhance both long-term 
potentiation and learning in mice [169]. 
The broad repopulation of human astrocytes as well as increased 
infiltration of peripheral immune cells in the brain of dual reconstituted mouse 
also provide us a promising opportunity to investigate the role of astrocytes in 
progressive viral infection.  
 In summary, we were able to successfully engraft neonatal NSG mice with 
NPCs and HSCs. The dual reconstituted chimeric mouse model contained 
both a human immune system and human glia. This model allowed us to 









Figure 3.1. Generation of dual reconstituted mice and properties of neural 
progenitor cells (NPCs). (A) Scheme of the transplantation of human blood 
and brain progenitors at birth and the period of observation. Humanization of 
bone marrow and secondary lymphoid tissues are shown in red. Humanization 
of brain (blue with yellow dots) is shown by enlarged view of sagittal section 
(1×) stained for human-specific cytoplasmic marker by STEM121 antibodies 
(Takara Bio USA). (B) Example of neurosphere in culture. Image obtained by a 
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Nikon TE300 microscope (Nikon Instruments, Inc., Melville, NY, USA) at 
original magnification of 200×. (C) Representative immunofluorescent images 
of 48-hour cultured single cells derived from neurospheres. Upper line panels 
show cells positive for glial fibrillary acidic protein (GFAP, green) and nestin 
(red), both known as progenitor cells with radial glia characteristics. Middle line 
panels demonstrate cells stained by microtubule-associated protein 2 (MAP2; 
green) and GFAP (red) antibodies, which are considered to be early stage glial 
precursors. Lower line panels show cells positively stained by the neuronal 
marker glutamic acid decarboxylase 67 (GAD67; green) and class III β-tubulin 
(Tuj-1; red). Original images were captured by a Zeiss LSM510 system (Carl 
Zeiss Microscopy GmbH, Jena, Germany) with 400× magnification. Bar = 50 

















Figure 3.2. Glial humanization of the mouse brain. (A) Animals were analyzed 
at 6 months of age. Human astrocyte specific antibodies (red) and 
non-species-specific total glial fibrillary acidic protein (GFAP; green) staining 
was done in different brain regions. Original images were collected by a Leica 
DM6 system (Leica Microsystems, Wetzlar, Germany) with 1000× 
magnification. Nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI; 
blue). Bar = 20 µm. (B) Oligodendrocyte specific nuclear staining (Olig2; 
green) and total human-specific nuclear (hN) staining was done in different 
brain regions. The original magnification was 400×. Bar = 50 µm. Results from 
one of two performed experiment are shown. (C) Quantitative data showing 
the number of human astrocytes from one of four experiments with ten 
animals. The average percentage of human cells was assessed on 2–4 
representative sagittal sections from each mouse for a selected field of view of 
the same brain region. Each symbol represents an individual mouse and lines 
indicate mean and standard error of the mean (SEM). (D) Proportion of human 
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oligodendrocytes among human glial cells in different brain regions. Dotted 




























Figure 3.3. Immune repopulation of peripheral blood and the mouse brain. (A) 
Fluorescence-activated cell sorting (FACS) analysis of peripheral blood. 
Representative plots of human cluster of differentiation 45 (CD45)+ cells and 
human CD3, CD19, and CD14 cells gated from the CD45 lymphocyte 
population. CD8 and CD4 cells were gated from CD45+ and CD3+ cell 
populations. (B) Percentage of human cells in peripheral blood of all dual 
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reconstituted mice used in the studies. Each symbol represents an individual 
mouse. (C) Representative images of the distribution of human immune cells 
in the brain. Paraffin embedded 5-µm thick sections were stained for 
human-specific markers: human leukocyte antigen-antigen D related 
(HLA-DR), CD163, CD4, and CD8. Representative images from different brain 
regions are shown. Images were captured by a Nuance multiplex system (CRi, 
Wobum, MA) with an original magnification of 200×. Insets represent cells with 
a magnification of 1000×. Bars = 100 µm and 20 µm (inset). (D and E) 
Quantification of human cells positive for HLA-DR, CD163, CD8, and CD4 in 
selected regions. Numbers represent frequencies of positive cells per section; 
7 mice were analyzed. Human-specific antibodies did not cross-react with 







Figure 3.4. Biological processes altered by humanization. Gene Ontology 
(GO) enrichment analysis for gene sets identified as differentially expressed 
according to mouse database and predicted biologic processes in mouse brain 












In PBa, % 
Viral copies/mL 
 in PB or 
IHC P24+ in spleenb 
1 
CD34+NPC 
842c F 49.0 1.89 x104 
844 F 64.3 2.05 x 106 
845 F 57.4 P24+ 
848 M 62.4 P24- 
843 F 52.2  
846 F 81.1  
847 F 85.1  
849 M 72.2  
850 M 60.0  
2 
CD34+NPC 
853 F 51.6 1.50 x 105 
854 F 48.1 6.14 x 105 
855 F 67.4 P24+ 
857 M 58.4 P24+ 
858 M 49.6 3.30 x 105 
851 F 55.3  
852 F 34.8  
856 M 39.4  
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859 M 59.5  






861 F 87.2 P24+ 
862 F 88.3 6.30 x 104 
864 F 93.4 P24+ 
867 M 86.8 P24+ 
868 M 75.6 3.05 x 104 
869 M 48.7 1.15 x 105 
865 F 82.3  
866 F 70.8  
870 M 67.9  
871 M 68.6  
4 
CD34+NPC 
881 F 43.0 P24+ 
883 F 45.1 P24+ 
884 F 54.8 P24+ 
885 F 57.3 3.90 x 106 
886 F 67.8 9.19 x 105 
887 F 67.1 P24+ 
888 M 34.1 P24+ 
893 M 47.2 P24+ 
882 F 52.4  
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Table 3.1. Animal information. 
a. PB, peripheral blood 
b. IHC P24, positive staining of human cells for HIV-1 p24 protein in spleen 
sections 
c. Red font color indicates mice infected with HIV-1. 






889 M 58.1  
890 M 20.2  
891 M 64.2  
892 M 38.6  
894 M 46.3  
895 M 51.3  
896 M 78.2  
5d 
CD34 
2464 F 68.0  
2465 F 69.8  
2466 F 65.6  
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NSG 1 51014897 48087583 94.26    
NSG 2 41652143 39018734 93.68    
NSG 3 46959446 44511795 94.79    
865 46956130 43421923 92.47 3634305 1372101 37.75 
866 40829365 37037892 90.71 3922047 1960111 49.98 
870 50793540 47210898 92.95 3669575 1210544 32.99 
862-HIV 43135303 39972433 92.67 3229431 838062 25.95 
868-HIV 35981612 31455849 87.42 4596462 984201 21.41 



























NSG 1 45441189 43553086 95.84    
NSG 2 30165210 26937369 89.30    
NSG 3 41990884 39445457 93.94    
865 45264610 42909810 94.80 2398270 622385 25.95 
866 38643985 36193215 93.66 2499633 722320 28.90 
870 46034814 43766894 95.07 2294914 398541 17.37 
862-HIV 50495226 47149758 93.37 3415952 962671 28.18 
868-HIV 41272990 38694696 93.75 2626259 683299 26.02 
869-HIV 50576101 47508501 93.93 3131638 840446 26.84 
Table 3.2. RNA sequencing summarya 
a - RNA sequences generated from high-throughput sequencing were aligned 
to the mouse genome (mm10). Resultant unaligned sequences were then 





3.5  Materials and Methods  
3.5.1 Animals, cell transplantation 
Newborn NOD/SCID/IL2Rγc−/− (NSG, stock No: 005557, The Jackson 
Laboratory, Bar Harbor, ME, USA) mice were bred at the University of 
Nebraska Medical Center (UNMC). P0-1 litters were irradiated with 1 Gy (RS 
2000 X-ray Irradiator, Rad Source Technologies, Inc., Suwanee, GA, USA). 
Pups were intrahepatically injected with 5 × 105 CD34+ HSCs. These mice 
were simultaneously transplanted with 1 × 105 NPCs into the right lateral 
ventricle. Blood samples collected from the facial vein were evaluated by flow 
cytometry starting 8 weeks post-engraftment to monitor expansion of human 
leukocytes. Mice characteristics are listed in Table 3.1. Animal procedures 
strictly followed the Institutional Animal Care and Use Committee-approved 
protocols at UNMC. 
 
3.5.2 Neural progenitors isolation and culture 
Human neural progenitors were isolated from human fetal brains provided by 
the University of Washington Medical Center Laboratory of Developmental 
Biology (R24HD000836-51). The protocol was approved by the UNMC 
Scientific Research Oversight Committee (SROC) and Institutional Review 
Boards at the University of Washington Medical Center and UNMC. Cell 
isolation and culture were done as previously described [196]. Briefly, single 
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cell suspensions were cultivated in NS-A medium (STEMCELL, Mountain 
View, Canada) containing N2 supplement (1:100; Fisher Scientific, Waltham, 
MA, USA), neural survival factor-1 (NSF1; 1:50; Lonza, Walkersville, MD, 
USA), LIF (10 ng/ml; Sigma-Aldrich, St. Louis, MO, USA), epidermal growth 
factor (EGF; 20 ng/ml; Fisher, MA, USA), and basic fibroblast growth factor 
(bFGF; 20 ng/ml; STEMCELL, Mountain View, Canada) for 14 days before 
passage. Four hours before injection, the neurospheres were dissociated into 
single cell suspension with 0.25% Trypsin (Gibco, Grand Island, NY, USA). 
The single cell suspensions were plated on polystyrene-coated coverslips and 
cultured for 48 hours in vitro. Immunofluorescent cytology was applied to 
investigate the differential potential of NPC. 
 
3.5.3 Human hematopoietic stem cells (HSCs) isolation 
Matched to the brain sample, fetal liver tissue was processed with 0.5 mg/ml 
DNase, collagenase, and hyaluronidase (all from Sigma-Aldrich, St. Louis, 
MO, USA) using gentleMACS™ Dissociator (Miltenyi Biotec, Auburn, CA, 
USA). Cell suspensions were passed through a 40-µm cell strainer and then 
centrifuged through leukocyte separation medium (MP Biomedicals, Santa 
Ana, CA, USA) at 100 g for 30 min, with acceleration set to 9, and deceleration 
set to 1. The intermediate layer of cells was collected for positive isolation of 
CD34+ cells using a magnetic isolation kit (Miltenyi Biotec, Auburn, CA, USA). 
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CD34+ cells were stored in liquid nitrogen using a freezing medium with 50% 
fetal bovine serum (FBS), 40% Roswell Park Memorial Institute (RPMI)-1640 
medium (Hyclone, Logan, UT, USA), and 10% dimethyl sulfoxide (DMSO; 
Sigma-Aldrich, St. Louis, MO, USA). 
 
3.5.4 Flow cytometry 
Blood samples were collected from a facial vein in ethylenediaminetetraacetic 
acid (EDTA)-containing tubes (BD Microtainer, Franklin Lakes, NJ, USA) and 
centrifuged at 300 g for 5 min. Plasma was stored for HIV viral load 
measurements. Blood cells were reconstituted in a buffer of 2% FBS in 
phosphate buffered saline and incubated with antibodies against human cell 
markers, including CD45+ fluorescein isothiocyanate (FITC), CD3+ Alexa700, 
CD19+ R-phycoerythrin (PE) cyanine 7 (Cy7), CD4+ allophycocyanin (APC), 
CD8+ Brilliant VioletTM 450 (BV450), and CD14+ PE for 30 min at 4°C. 
Information on all of the antibodies are listed in S3 Table. Samples were 
analyzed using a BD LSR2 flow cytometer [182]. Gates were assigned 
according to the appropriate control population. 
 
3.5.6 Immunohistochemistry 
Brain tissue was cut sagittally for both the left and right hemispheres, fixed with 
4% paraformaldehyde for 24 hours at 4°C, and then embedded in paraffin. 
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Paraffin-embedded 5-m thick tissue sections were processed with Declere 
Solution (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s 
instructions. Tissue was blocked with 10% normal goat serum in Tris-buffered 
saline and 0.05% Tween 20 (TBST) for 45 min and then incubated with mouse 
(ms) anti-human GFAP (1:200; Abcam, Cambridge, MA, USA), ms anti-human 
nuclear antigen (1:200; Millipore, Billerica, MA, USA), ms anti-human 
cytoplasmic marker (1:1000; STEMCELL, Mountain View, Canada), ms 
anti-HIV-1 p24 (1:10; Dako, Carpinteria, CA, USA), ms anti-HLA-DR (1:500; 
Dako, Carpinteria, CA, USA), ms anti-CD163 (1:50; Thermo Scientific, Denver, 
CO, USA), rabbit (rb) anti-GFAP (1:1000; Dako, Carpinteria, CA, USA), and rb 
anti-human CD4 (1:500; Abcam, Cambridge, MA, USA). Secondary antibodies 
were goat anti-ms and goat anti-rb immunoglobulin G (IgG) horseradish 
peroxidase (HRP; Dako, Carpinteria, CA, USA). Bright field images were 
captured and photographed using 20× and 100× objectives on a Nuance 
Multispectral Tissue Imaging system (CRi, Wobum, MA). Immunostained 
sections were scanned using a high-resolution scanner (Ventana Medical 
Systems, Inc., Oro Valley, AZ, USA). DEFINIENS Tissue Studio® software 
(Definiens AG, Munich, Germany) was used to analyze the brain sections 
stained for human glial and immune cells. None of human-specific antibodies 




For immunofluorescent staining of paraffin-embedded tissue, sections were 
processed and blocked as described above. Ms anti-human GFAP (1:200; 
Abcam, Cambridge, MA, USA), ms anti-human nuclei (1:200; Millipore, 
Billerica, MA, USA), rb anti-GFAP (1:1000; Dako, Carpinteria, CA, USA), and 
rb anti-Oligo2 (1:500; PhosphoSolutions, Aurora, CO, USA) were applied. For 
immunofluorescent characterization of cultivated NPC, ms anti-human GFAP 
(1:200; Abcam, Cambridge, MA, USA), ms anti-MAP2 (1:200; Santa Cruz, 
Santa Cruz, CA, USA), ms anti-glutamic acid decarboxylase 67 (GAD67; 
1:500; Millipore, Billerica, MA, USA), rb anti-nestin (1:200; Millpore, Billerica, 
MA, USA), and rb anti-Tuj-1 (1:500; Biolegend, San Diego, CA, USA) were 
applied. Secondary antibodies were goat anti-ms IgG Alexa 488 (1:00; 
Invitrogen, Grand Island, NY, USA), goat anti-ms IgG Alexa 594 (1:00; 
Invitrogen, Grand Island, NY, USA), goat anti-rb IgG Alexa 488 (1:100; 
Invitrogen, Grand Island, NY, USA), and goat anti-ms IgG Alexa 594 (1:00; 
Invitrogen, Grand Island, NY, USA). A Leica DM6 system (Leica 
Microsystems, Wetzlar, Germany) and a Zeiss LSM510 confocal system (Carl 
Zeiss Microscopy GmbH, Jena, Germany) were also used for 
immunofluorescent imaging. The intensity of illumination and the position of 
the sub-region on the microscope were consistent across all images.  
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3.5.8 RNA isolation and next generation sequencing 
Left hemispheres of the reconstituted mouse brains were preserved in 
RNALater (Invitrogen, Grand Island, NY, USA). The corpus callosum and 
hippocampus from three HIV-infected dual reconstituted mice, three control 
dual reconstituted mice, and three non-manipulated NSG mice were 
micro-dissected and transferred to 700 µl of QIAzol solution (QIAGEN, 
Valencia, CA, USA) for RNA isolation using an RNeasy Mini kit (QIAGEN, 
Valencia, CA, USA). After RNA integrity was analyzed, samples were deep 
sequenced using 100 bp/read, up to 40 million reads/sample using an Illumina 
HiSeq 2500 Sequence Analyzer (Illumina, Inc., San Diego, CA, USA). For both 
the hippocampus and corpus callosum, we compared the control samples 
(NSG1–3) to the humanized mouse samples (865, 866, 870), and the 
humanized mouse samples to the humanized mouse samples with HIV (862, 
868, 869). The reads were mapped to the mm10 mouse genome and the 
mouse transcriptome. A third comparison was also made whereby humanized 
mouse samples (865, 866, 870) were compared with humanized mouse 
samples with HIV (862, 868, 869), but mapped to the hg19 human database. 
For both tissues, we collected the unmapped reads, which did not map to the 
mouse genome, and remapped them to the human genome. This was done in 
order to see what human genes were expressed in these tissues. The cuffdiff 
algorithm was used to identify differentially expressed genes; all significant 
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genes were reported with an FDR adjusted p-value of 5% for all cuffdiff 
comparisons. Cuffdiff was specifically used because it normalizes the 
expression values and protects against overdispersion so that the values fit 
into a normalized bell curve [200]. The number of total reads and alignment 
results are shown in Table 3.2.  
 
3.5.9 Statistical analysis 
Values from all quantifyed cell types (astrocytes, oligodendrocytes, 
macrophages and lymphocytes) and groups were averaged; multiple t-tests 
using the Holm-Sidak method for multiple comparisons correction was applied 
to examine significant differences between groups. Two-way analysis of 
variance (ANOVA) using Sidak’s multiple comparisons correction was used to 
examine significant differences between groups. For RNA sequencing data, 
the tophat/cuffdiff pipeline was run on the reads for each sample in order to 
















CHAPTER - 4 
HIV-1 Infection and Glial Innate Immune Response in 













A mouse model with dual humanized brain and immune system was created to 
bridge the gap in deciphering complex neuroimmune communication networks 
seen during progressive HIV-1 infection. Immune analyses of these 
HIV-1-infected mice showed meningeal and perivascular infiltration by human 
leukocytes and surveillance by activated immune cells in brain tissue. The 
molecular mechanisms underlying species-specific virus-immune system-brain 
tissue interactions were identified by deep RNA sequencing. In the corpus 
callosum and hippocampus of HIV-1 infected animals overlapping 
human-specific transcriptional alterations were seen for interferon (IFN) type 1 
and 2 signaling pathways (STAT1, 2, IRF9, MX1, ISG15, IFI6, CMPK2) and a 
range of host antiviral responses. Human viral defense mechanisms including 
linked cytokine signaling patterns closely resembled what was observed by 
others in human HIV-1 encephalitic brains. Differentially expressed mouse 
genes in the hippocampus reflected tissue remodeling while down-regulated 
human genes were linked to altered cell growth, glial cytoskeleton 
reorganization, oligodendrocyte differentiation and myelin ensheathment 
(MBP, MOBP, PLP1, MAG and ZNF488). These results were confirmed by 
real-time PCR tests. We conclude these mice can provide human 
disease-specific viral-glial communication cues and may facilitate discovery of 
new therapeutics targets for HIV-1 nervous system infection. 
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4.2 Introduction  
Although the HIV-infected humanized mouse models have been characterized 
extensively for their ability to recapitulate the human immune response against 
HIV, and been applied widely to test the efficacy of therapeutic approaches, 
they are insufficient to assess HIV-associated neuropathology and related 
neurocognitive dysfunctions. As introduced in the previous chapter, a new 
mouse models with combined human immune system and glial cells (primarily 
astrocytes and oligodendrocytes) reconstitution were created to further dissect 
neuroimmune interactions during progressive HIV-1 infection.  
We investigated the pathological and molecular changes in this dual 
reconstituted mouse model after being infected with macrophage-tropic 
HIV-1ADA. The Immune analyses of these HIV-1-infected mice showed 
meningeal and perivascular infiltration by activated human immune cells in 
brain tissues. Deep RNA sequencing revealed transcriptional signatures that 
were linked to activation of IFN type 1 and 2 signaling pathways (STAT1, 2, 
IRF9, MX1, ISG15, IFI6, CMPK2) and a range of host antiviral responses in 
HIV-1 infected animals. While down-regulated human genes were linked to 
altered cell growth, glial cytoskeleton reorganization, oligodendrocyte 
differentiation and myelin ensheathment (MBP, MOBP, PLP1, MAG and 
ZNF488). The results surprisingly overlapped with the disease profile observed 
by others in human HIV-1 encephalitic brains. This new model provided a 
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promising future for study of human-specific viral-glial interactions and 
discovery of new therapeutics targets for HIV-1 nervous system infection. 
 
 
4.3 Results  
4.3.1 HIV-1 infection of dual humanized mice 
As described in Chapter 3, the dual humanized mice were created by 
transplanting newborn NOD/SCID/IL2Rγc−/− mice both with human NPCs and 
HSCs. At 24 weeks of age, mice were divided into two groups. Each showed 
similar human immune reconstitution. One group was infected with HIV-1ADA 
intraperitoneally with 104 infectious particles in a volume of 100 µl/mouse. At 6 
weeks after infection, HIV-1 p24+ stained cells were present in the spleens (Fig 
4.1 A), with a median of 1.58 × 105 viral RNA copies/ml in blood (Fig 4.1 B). 
Peripheral immune cells infected by HIV were in the meninges but rarely in the 
perivascular space (Fig 4.1 C). Flow cytometric analyses performed at 6 
weeks after infection showed a drop from 80% to 60% of CD4+ T cells among 
the CD3+ population (P < 0.05). An increase in the CD8+ T lymphocytes was 
seen in a proportion to CD4+ T cell depletion (Fig 4.1 D and E).  
An unbiased digital image analysis workstation (DEFINIENS Tissue 
Studio®, Cambridge, MA, USA) was used to analyze human glial cell 
repopulation and immune cell brain infiltration. In comparison to non-infected 
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controls, HIV-1-infected mice had a lower number of human astrocytes/sagittal 
section. However, the total number of nucleated cells/sagittal section remained 
consistent across the animal groups (Fig 4.1 F). A statistically significant 
two-fold increase in the number of brain infiltrating peripheral immune cells 
following HIV-1 infection was observed when compared to uninfected dual 
reconstituted mice (Fig 4.1 G). However, the presence of human glial cells did 
not increase the numbers of human leukocytes within the meninges and 
parenchyma compared to age-matched peripherally reconstituted humanized 
mice. 
 
4.3.2 Transcriptional changes in the humanized mouse brain 
To assess the pathobiological outcomes of viral infection following peripheral 
immune and brain humanization, we applied deep sequencing to assess 
transcriptional profiles seen as a consequence of glia-immune crosstalk. We 
selected three infected animals with similar patterns of human immune cell 
repopulation, astrocyte distribution and peripheral viral loads for study. Three 
equivalent aged NSG uninfected mice served as controls (Fig 4.2 A). Hip and 
CC repopulated by human glial cells were dissected for sequencing (Fig 4.2 
C). All sequenced reads (~100 bp length) were aligned to the mouse database 
(University of California Santa Cruz Genome Browser database, 
GRCm38/mm10). The experiment was designed to search for differentially 
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expressed mouse transcripts as a result of human cell engraftment and 
HIV-1-infection. Subsequently, the reads unmapped to the mouse genome 
were re-aligned to the human genome (GRCh38/hg19) to find human specific 
transcriptional changes. The overall mapped mm10 reads average ratio was 
92% for all 9 Hip samples and 94% for all 9 CC samples (Table 3.2). For the 
HIV-1-infected and uninfected humanized mice, the mouse database was run 
against its human counterpart. The average ratio for mapped reads was 32% 
and 26% for the Hip and CC, respectively. Analyses using the mouse 
database identified 365 differentially expressed transcripts in the Hip and 93 in 
the CC as a result of the engraftment of human glial cells. When compared to 
humanized mouse transcripts, few mouse transcripts were differentially 
expressed as a result of HIV-1 infection. When the reads unmapped to the 
mouse genome were realigned to the human reference genome, 115 and 58 
human transcripts were found differentially expressed in the Hip and CC, 
respectively, following infection (Fig 4.2 D). The low numbers of HIV-1gag 
RNA was detected in selected brain regions (Fig 4.2 B). The alignment to 
HIV-1ADA genome detects gag (1), pol (3), tat (2) and vif (1) reads of transcripts 
in CC of two animals. In Hip samples of infected animals HIV-1 mRNA 
transcripts were not found. 
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4.3.3 Region-specific alterations of mouse transcriptom by HIV-1 
infection in combinatorial humanized mice  
We used GeneCards® integrative database to obtain categorized results for 
differentially expressed mouse genes. This was done to identify Gene 
Ontology (GO) gene sets related to mouse brain humanization. The obtained 
information about the biological roles of the genes of interest we summarized 
in Fig 3.4 Glial humanization of mouse brain with a human peripheral immune 
system induced transcriptional changes associated with multiple biological 
processes. The complete set of differentially expressed genes for mouse 
transcriptome comparisons between NSG and HIV-1 infected humanized mice 
is listed in the 4.1 Table. 
 
4.3.4 Non-overlapping alterations in the human and mouse 
transcriptomes following viral infection  
In comparison to uninfected mice, brains with virus-infected human showed 
signature expression patterns of 45 and 56 genes in the CC and Hip, 
respectively (Fig 4.2 E). In the CC, the up-regulated genes were strongly 
associated with type 1 and 2 IFN responses and specific signaling pathways. 
These were linked to host viral defense responses (MX1, IFIT families, 
PLSCR1, EIF2AK2, IFI16, ADAR, OAS3, MX1, BST2, RSAD2), RNA 
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catabolism (CMPK2, PNPT1), ISG15-protein conjugation, regulation of type 1 
IFN production (HERC6, ISG15, DXT3L, DDX58, PPAR9, PPM1K) and 
cytokine-mediated signaling (Table 4.2).  
In addition, up-regulated genes associated with norepinephrine metabolic 
processes (EPAS1, LY6E) and those related to neural differentiation 
(PARP10, GARS, AGRN, SOX10) were found. In the CC and Hip, the 
identified down-regulated genes were linked to myelination and axon 
ensheathment (MBP, MOBP, MAG, PLP1, CLDN11), neural progenitor 
differentiation (STMN2, ZNF488, IGFBP5, BIN1, APLP1), glial structural 
integrity, lipid metabolism, ion transportation and cell cycle regulation (Table 
4.2 and 4.3). Alignment to the mouse database reads in the uninfected and 
HIV-1-infected humanized mice showed non-overlapping up-regulated gene 
patterns. These were related to blood vessel development and extracellular 
matrix re-organization (ALDH1A2, TCF7L2, COL1A2, COL5A1, FMOD, BMP7) 
as well as neurotransmitters, sugars, organic acids, anion transmembrane 
transport (SLC6A13, SLC6A20, SLC22A6, SLC13A4), and cellular responses 
to hormone stimulus (IGFBP2, RAMP3). Few down-regulated genes were 
observed (ST18, CMSS1). The obtained by GeneCards® integrative data base 
information about the biological roles of the genes of interest we summarized 
in Fig 4.4. The identical biologic processes were found in CC and Hip that 
characterize the well-known responses of human glial cells and immune cells 
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to HIV-1 infection. The mouse biological responses to HIV-1 infection in this 
new chimeric system were not virus or immune responses related.  
 
4.3.5 Human astrocytes produce type 1 IFN during infected 
macrophage-astrocyte co-cultivation 
The up-regulated expression of type 1 IFN and the related response in the 
chimeric murine brains following HIV-1 infection led to investigation of the type 
1 IFN cell source. Though almost all nucleated cells can produce type 1 IFN, 
plasmacytoid dendritic cells are the most potent IFN producers [201]. 
However, prior studies have demonstrated that astrocytes abortively infected 
by neurotropic viruses are also a potent source of IFN beta (IFN-β) in mice 
[186]. To identify the source of type 1 IFN in response to HIV-1 infection, we 
used transwell systems to co-culture human fetal astrocytes and 
HIV-1-infected monocyte-derived macrophages (MDM). After 3 days of 
co-culture with HIV-1-infected MDM and astrocytes, astrocytes were found to 
produce IFN-β. The levels of IFN-β reached a peak at 5 days. Three 
independent donors were used; a representative experiment is shown in Fig 
4.5. The concentration of IFN-β produced by HIV-infected MDM alone 
remained at relatively low levels (approximately 15 pg/ml, detection limit). The 
concentration of IFN-β in control astrocytes and MDM were below detectable 
throughout the experimental observation period.  
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4.3.6 RT-PCR confirmation of affected human genes in humanized 
mouse brain tissues 
To confirm the altered expression and the species specificity of the IFN 
signaling pathway related transcripts, we applied real-time PCR assays to 
reexamine the selected genes found affected in RNA-sequencing using human 
and mouse specific primers and probes.  As critical elements of the upstream 
of type 1 IFN response pathway, STAT1, STAT2 and IRF9 were found 3.72, 
1.69, and 3.64 times (P<0.05) up-regulated in the CC of HIV-1-infected dual 
reconstituted mice, respectively, compared to that of control dual reconstituted 
mice. Up-regulation of these three genes was found in the Hip of HIV-infected 
humanized mice as well (Fig 4.6 A - C).  The down-stream IFN inducible 
genes such as MX1, ISG15, IFI6 and CMPK2 were also found significantly 
up-regulated in both CC (12.09, 11.69, 9.41 and 13.69 times, respectively, 
P<0.05) and Hip (19.90, 15.90, 9.17 and 21.25 times, respectively, P<0.05) of 
HIV-1 infected humanized mice compared to the control animals (Fig 4.6 D - 
G). Among the myelination and glial integrity associated genes, the expression 
of MBP was reduced 2.94 and 2.5 times (P<0.05) in the Hip and CC of HIV-1 
infected mice, respectively (Fig 4.6 H). The expression of ZNF488 was only 
found significantly down-regulated in the CC of HIV-1 infected group, but not in 
the Hip (Fig 4.6 I). The assays using mouse-specific primers and probes failed 
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to demonstrate any gene expression difference between HIV-1 and control 
groups. 
 
4.4 Discussion  
We created a unique mouse model that contains both a human immune 
system and human glial cells in the brain. The animals were used to 
investigate the consequences of HIV-1 infection on brain pathobiological 
processes. Sustained infiltration of lymphocytes and macrophages were 
readily seen and altered nervous system microenvironment [177]. These 
results paralleled a previously demonstrated accelerated entry of human 
CD163+ macrophages and T lymphocytes into the brains of infected 
humanized mice in the absence of glial reconstitution [182]. Specifically, 
increased numbers of HLA-DR cells infiltrated into dual reconstituted mouse 
brains. This was seen in comparison to mice reconstituted only with a human 
immune system. Moreover, an increased number of human leukocytes 
infiltrated glial reconstituted brains after systemic infection.  
As the most abundant cell type in the brain, astrocytes react to injury or 
viral infection through cellular activation [202]. Inefficient viral entry due to lack 
of CD4-receptors and limited expression of CXCR4 and CCR5 has been 
suggested as a major obstacle to astrocyte infection [203]. Thus, while most 
researchers would agree that highly restricted infection of astrocytes can occur 
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[204] whether it can affect brain homeostatic and antiviral responses was not 
previously recognized in depth. In the present study we found low levels of 
HIV-1gag mRNA expression in infected mice brains and failed to find human 
astrocytes that were HIV-1p24 protein positive by immunohistology. Very 
limited number of viral mRNA transcripts were detected in CC of two animals, 
when sequencing reads were aligned to HIV-1ADA genome, while in Hip 
samples of infected animals HIV-1 mRNA transcripts were not found. 
Nonetheless, significant innate human antiretroviral responses were observed 
in these chimeric mice.  
For the first time, combinatorial blood-brain humanized mice were made, 
infected with HIV-1 then analyzed by RNA-sequencing for species-specific 
reaction. We followed a similar strategy to that of chimeric tissue 
transcriptomic analysis described for humanized mice carrying syngeneic 
tumor and immune tissues. In this case humanizing mouse bone marrow 
enables microenvironment reconstitution in a patient-derived xenograft [205]. 
Comparison of transcriptional changes in the immune responses of humans 
and mice associated with the non-species-specific bacterial pathogen S. 
aureus, has shown to be highly correlative [206]. Nevertheless, transcriptional 
changes induced in the brain of chimeric animals by HIV-1 should be 
human-specific. Indeed, our findings in the transcriptome of HIV-1-infected 
dual reconstituted mice corroborated this idea. More than 30 human genes 
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significantly up-regulated in the CC and Hip were found to be closely related to 
innate and adaptive immunity, HIV host restriction factors, and IFN stimulated 
factors (Table 4.2 and 4.3). Noticeably, STAT1/STAT2 and IRF9 can form a 
transcriptional complex upon activation of type 1 IFN receptors [207]; this 
complex can subsequently translocate to the nucleus and induce the 
expression of a broad spectrum of IFN-stimulated genes [208]. Among these 
IFN stimulated factors, MX1, OAS3, RSAD2 (viperin), and all the IFI and IFIT 
family are involved in combating viruses at nearly every stage of the viral life 
cycle. For instance, IFN-inducible transmembrane proteins (IFITMs) and 
tripartite motif proteins (TRIMs) can act during viral entry and uncoating [209]. 
Myxoma resistance proteins (MXs) block nucleocapsid transport [210]. 
Inhibition of RNA reverse transcription, protein translation, and stability are 
mediated by SAM-domain- and HD-domain-containing protein 1 (SAMHD1), 
adenosine deaminase, RNA-specific 1 (ADAR1), 2′-5′ oligoadenylate 
synthases (OASs), IFN-stimulated gene 20 kDa protein (ISG20), and ISG15 
[120, 211-213]; viperin and tetherin help to prevent viral assembly and release, 
respectively [214-216]. Some of the effectors, such as MX proteins, appear to 
operate in both the nucleus and the cytosol [210]. Therefore, human glial cells 
in the mouse brain are able to restrict, in measure, productive viral infection 
through a robust type 1 IFN response. The up-regulation of the human specific 
IFN signaling related genes were confirmed by real-time PCR assays using 
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human specific primers and probes (Fig.4.6). We also confirmed by RT-PCR 
upregulation of rare mRNA transcript identified by RNA sequencing for 
CMPK2, which could belong to infiltrating human macrophages and serve as a 
viral restriction factor [217]. However, no change in expression of the host 
restriction factors were reflected in the mouse transcriptional profile as result of 
HIV-1 infection, which is consistent with the confirmatory real-time PCR 
assays. This observation reflects that HIV-1 can neither efficiently enter mouse 
cells due to the absence of specific receptors, nor trigger a pattern recognition 
response by murine cellular defense machinery. 
This vigorous type 1 IFN further leads to the question of what cell source 
produces type 1 IFN in these dual reconstituted mouse brains. Due to the 
increased infiltration of macrophages into the brain during systemic HIV-1 
infection in these mice, and astrocyte production of IFN-β[186], we were able 
to confirm the source of IFN-β; we posit that astrocyte secretion of IFN-β 
occurs through its interactions with infected macrophages. The transwell 
co-culture of HIV-1ADA-infected MDM and astrocytes revealed the temporally 
dependent dynamics of IFN-β production. 
Through the use of unbiased image analysis we found a limited yet 
significant decrease in the number of human astrocytes in the brains of 
chimeric mice infected with HIV-1. The cellular machinery that astrocytes used 
to protect themselves from productive viral infection could create an 
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inflammatory cascade. This could then lead to restricted astrocyte infection 
and programmed cell death [218]. A similar scenario is known to occur in 
quiescent CD4 T cells, which undergo an abortive infection with accumulation 
of incomplete HIV reverse transcripts [219]. In support of this theory, our data 
showed significant up-regulation of genes serving as cytoplasmic sensors for 
nucleic acids, such as DDX58 and IFI6. The downstream signaling and effects 
of these single- and double-strand RNA sensors in astrocytes are therefore 
worthy of further investigation. 
Furthermore, the deep sequencing also captured several significantly 
up-regulated transcripts in the chimeric brains, such as C19orf66, which has 
potential as an IFN-stimulated inhibitor of the dengue viral infection [220]. 
Moreover, the lectin, galatoside-binding, soluble 3 binding protein 
(LGALS3BP) has been found to be elevated in the serum of HIV infected 
patients and is involved in interference with the incorporation of HIV-1 
envelope glycoprotein molecules into virions [221]. In the Hip, in addition to the 
up-regulated genes introduced previously, class I HLA genes were also found 
to be up-regulated, which is yet another downstream effect of the type 1 IFN 
response.  
The identified down-regulated genes are mostly critical for oligodendrocyte 
differentiation and myelination, cell growth, and glial structural constituents. 
Among them, zinc finger protein 488 (ZNF488) is a critical transcriptional factor 
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that interacts and cooperates with Olig2 to promote oligodendrocyte 
differentiation [222]. PLP1, MAG, MOBP, and MBP are encoding structure 
proteins of the myelin sheath. CLDN11 encodes a crucial component of the 
tight junctions between the myelin sheath [223]. In claudin11 knockout mice, 
action potential propagation was compromised due to the dissipation of 
electrical current through myelin [224]. Together, all of these molecular 
changes suggest early alterations in the structure and function of white matter 
during HIV infection. This may potentially lead to a compromise in the integrity 
of the glial system and consequent neural dysfunction. For example, a 
previous study showed decreased expression of myelin proteins, like MOG 
and MAG, from 12–17 weeks post-infection in humanized mice only 
reconstituted with a human immune system [183]. Additionally, the 
transcriptional changes in HIV-1 transgenic rat also demonstrated a decreased 
expression of genes encoding myelin proteins in regions like frontal cortex and 
striatum [225]. Our dual reconstituted mice were only observed for 6 weeks 
after infection, and human-specific transcripts were already down-regulated. 
Therefore, a longer period of infection may be necessary for observing 
transcriptional and morphological changes in mouse oligodendrocytes and 
myelin structure. This new model is a step forward as compared to other 
humanized mice that are widely utilized for HIV-1 research notwithstanding the 
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additional need for human neurons to fully assess HIV-1-associated 
neuropathology.  
 In summary, the dual reconstituted chimeric mouse model allowed us to 
investigate how glial-immunocyte crosstalk is affected by HIV-1 infection. 
Using sequencing we found that the transcriptional profiles from the chimeric 
brains overlap, in large measure, with the disease profile found in human 
HIV-1 encephalitic brains [176, 226]. These findings underscore the protective 
role astrocytes have in defending the brain from HIV-1 infection. This model 
also provides a platform to further investigate the HIV nervous system 
























Figure 4.1. Effects of HIV-1 infection on dual blood and brain humanized mice. 
(A) Immunohistology of spleen sections shows clusters of human leukocyte 
antigen-antigen D related (HLA-DR) positive cells and the presence of 
HIV-1-infected cells stained for HIV-1 p24. Images were captured by a Nuance 
multiplex system (CRi, Wobum, MA) with an original magnifications of 200×. 
Bar = 100 µm. (B) Peripheral viral load determined by quantitative real-time 
polymerase chain reaction (PCR) using a COBAS Amplicor System (Roche 
Molecular Diagnostics, Pleasanton, CA, USA). Each symbol represents an 
individual infected mouse from all experiments. (C) Immunohistology of brain 
sections showing the presence of activated HLA-DR+ cells and HIV-1 p24+ 
infected cells on adjacent serial sections. Representative images from the 
meningeal space containing vascular vessels are shown. Images were 
captured by a Nuance multiplex system with an original magnification of 200×. 
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Insets represent cells with a magnification of 1000×. Bars = 100 µm and 20 µm 
(inset). (D) Examples of representative plots showing cluster of differentiation 
4 (CD4)+ cell decline in peripheral blood of HIV-1-infected mice, with a relative 
increase in the CD8+ cell compartment. (E) Quantification of human CD4 and 
CD8 T cells in the peripheral blood of infected (n = 6) and control (n = 6) mice. 
Multiple t-tests using the Holm-Sidak method for multiple comparisons 
correction was applied to examine significant differences between groups. 
Bars = means ± standard error of the mean (SEM); *P < 0.05. (F) 
Quantification of human glial fibrillary acidic protein (GFAP)+ and all nucleated 
cells on representative sagittal brain sections of HIV-1-infected (n = 18) and 
control (n = 19) mice. Unpaired t-tests were used to examine significant 
differences between groups. Bars = means ± SEM; *P < 0.05, ns = no 
significance. (G) Quantification of infiltrating HLA-DR+ and CD163+ cells in the 
brain regions of HIV-1-infected dual reconstituted mice (HIV-Dual hu, n = 5), 
control dual reconstituted mice (Control-Dual hu, n = 6), and mice only 
reconstituted with human peripheral immune cells (Control-Peri hu, n = 3). 
Two-way analysis of variance (ANOVA) using Sidak’s multiple comparisons 
correction was used to examine significant differences between groups. Bars = 















Figure 4.2. HIV-1 infection induced transcriptional changes in the brains of 
humanized mice. (A) Characteristics of peripheral reconstitution and the levels 
of HIV-1 infection of mice selected for ribonucleic acid (RNA)-sequence 
analysis (n = 3 per group). Percentage of lymphocyte sized cells, human 
cluster of differentiation 45 (CD45), CD3, CD4, and CD8 cells, as well as HIV-1 
viral load in the peripheral blood of HIV-1-infected dual reconstituted mice 
(HIV+, red symbols), control dual reconstituted mice (control, blue symbols), 
and non-manipulated non-obese diabetic (NOD)/severe combined 
immunodeficient (SCID)/interleukin 2 receptor γc (IL2Rγc)−/− control mice 
(NSG, grey symbols). (B) Viral RNA levels were determined by semi-nested 
real time polymerase chain reaction (PCR) in the HIV+ group (n = 3, red 
symbol) and the control group (n = 3, blue symbol). Viral nucleic copies were 
normalized to the total RNA quantity isolated from brain regions. (C) 
Representative image of human glial cell reconstitution and scheme of corpus 
callosum (CC) and hippocampus (Hip) microdissection. (D) Identification of 
differentially expressed transcripts in CC (upper pie chart) and Hip (lower pie 
chart). Sequenced reads were mapped to the mouse database (mm10) and 
comparisons were conducted: 1) between non-manipulated NSG mice and 
dual reconstituted NSG mice (NSG vs. huNSG, blue color); 2) between dual 
reconstituted NSG mice and HIV-1-infected dual reconstituted NSG mice 
(huNSG vs. HIV-huNSG, red color). Reads unmapped to the mm10 database 
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were realigned to the human database (hg19) and comparisons were 
conducted between dual reconstituted NSG mice and HIV-1-infected dual 
reconstituted NSG mice (unmapped huNSG vs. HIV-huNSG, green color). (E) 
Up- and down-regulated human genes in the CC and Hip of HIV-1-infected 
dual reconstituted mice compared to controls. Genes with an FDR adjusted P 


















Figure 4.3. Biological processes altered by HIV-1 infection. Gene Ontology 
(GO) enrichment analysis for gene sets identified as differentially expressed 
according to human and mouse data bases in HIV-1 infected humanized mice 










Figure 4.4. Production of IFN-β by astrocytes. Levels of human IFN-β were 
measured by enzyme-linked immunosorbent assay (ELISA) in the 
supernatants collected from astrocytes (Ast baseline, green), a co-culture of 
astrocytes and control monocyte-derived macrophages (Ctl-Ast-MDM, red), 
co-culture of astrocytes and HIV-infected macrophages (HIV-Ast-MDM, blue), 
HIV-infected macrophages (HIV-MDM baseline, purple), and control 
macrophages (Ctl-MDM baseline, orange). X-axis indicates the time points 
before (-6 days, -4 days, -2 days) and after co-culture (24 hours, 3 days, 5 
days, and 7 days). Data are expressed as the mean of triplicate technical 
replicates from one from three independent experiments (each done with 
distinct donors). Student t-tests were performed to compare HIV-Ast-MDM to 
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Ctl-Ast-MDM for each time point after co-culture. Bars = means ± standard 
















Figure 4.5. Real-time PCR confirmation of affected human genes in 
humanized mice brain tissues. Selected human gene expression profiles in the 
CC and Hip were confirmed by TaqMan® real-time PCR.  The HIV-1 infected 
(n = 6, red symbol) and control group (n = 5, blue symbol) are illustrated. The 
fold change in gene expression of human STAT1, STAT2, IRF9, MX1, ISG15, 
IFI6, CMPK2, MBP, and ZNF488 between the HIV-1 infected and the control 
groups were determined by using the 2−ΔΔCT method (A-I), where ΔCt = 
Cttarget – CtGAPDH and Δ(ΔCt) =ΔCtHIV – ΔCtcontrol. Multiple t-tests using 
Holm-Sidak method for multiple comparisons correction was applied to 
examine significant group differences. Bars = means ± standard error of the 
mean (SEM); *P < 0.05. 
 
	 114 













Up-regulated Genes in Corpus Callosum 
AGT 14.46 5.75 2.51 1.33 0.015 
PPOX 9.62 4.99 1.93 0.95 0.039 
GM3893 50.57 31.70 1.60 0.67 0.015 
HBB-BT 62.98 28.83 2.18 1.13 0.015 
COL4A2 11.41 6.85 1.67 0.74 0.015 
Down-regulated Genes in Corpus Callosum 
CRYM 2.10 24.89 0.08 -3.56 0.015 
FOS 7.85 18.11 0.43 -1.21 0.015 
EGR4 7.96 18.14 0.44 -1.19 0.015 
ARC 42.47 96.44 0.44 -1.18 0.015 
ARC 42.47 96.44 0.44 -1.18 0.015 
NR4A3 4.33 9.56 0.45 -1.14 0.015 
GPR17 4.28 9.30 0.46 -1.12 0.015 
SH3RF2 3.05 6.35 0.48 -1.06 0.015 
NR4A1 27.13 55.16 0.49 -1.02 0.015 
JUNB 18.35 36.80 0.50 -1.00 0.015 
EGR1 55.08 110.39 0.50 -1.00 0.015 
FOSL2 6.55 12.80 0.51 -0.97 0.015 
E330009J07RiK 8.27 14.96 0.55 -0.86 0.015 
EGR3 27.77 50.20 0.55 -0.85 0.015 
CTGF 7.59 13.42 0.57 -0.82 0.015 
HOMER1 40.59 68.88 0.59 -0.76 0.028 
DRD1A 22.25 34.79 0.64 -0.65 0.015 
PER1 20.53 31.09 0.66 -0.60 0.039 
Up-regulated Genes in Hippocampus 
LY6C1 33.18 64.66 1.95 0.96 0.005 
CYSTM1 17.93 34.61 1.93 0.95 0.033 
PVALB 43.07 80.99 1.88 0.91 0.005 
GM3893 17.55 32.87 1.87 0.91 0.005 
DCN 27.02 49.13 1.82 0.86 0.005 
HBB-BT 29.60 53.18 1.80 0.85 0.015 
CDR1 11.96 21.19 1.77 0.83 0.005 
MYL6B 8.54 14.95 1.75 0.81 0.044 
RGS11 12.04 20.53 1.71 0.77 0.005 
GABRA3 14.91 24.72 1.66 0.73 0.005 
GGACT 14.57 24.13 1.66 0.73 0.036 
COX7C 203.55 334.28 1.64 0.72 0.005 
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NTSR2 86.62 140.13 1.62 0.69 0.005 
ZNHIT2 15.71 25.33 1.61 0.69 0.015 
USMG5 381.13 603.23 1.58 0.66 0.005 
ATP11B 17.97 28.35 1.58 0.66 0.005 
TMSB10 118.08 185.82 1.57 0.65 0.005 
CLDN10 34.45 54.13 1.57 0.65 0.012 
FKBP1B 23.56 36.42 1.55 0.63 0.036 
MT2 193.84 296.45 1.53 0.61 0.005 
SERPINI1 55.50 84.08 1.51 0.60 0.005 
NRSN1 70.07 105.98 1.51 0.60 0.005 
2610203C20RIK 11.98 18.01 1.50 0.59 0.033 
SLC25A28 17.05 25.59 1.50 0.59 0.041 
RPL39 379.47 568.09 1.50 0.58 0.005 
DZIP1 16.48 24.62 1.49 0.58 0.005 
AQP4 47.27 70.38 1.49 0.57 0.005 
MGST3 85.94 127.68 1.49 0.57 0.020 
SLC25A18 45.76 67.81 1.48 0.57 0.012 
ID2 54.62 80.92 1.48 0.57 0.005 
DDX26B 12.47 18.39 1.48 0.56 0.017 
DTNBP1 33.04 48.61 1.47 0.56 0.015 
MAP4K2 16.92 24.74 1.46 0.55 0.017 
RIAN 139.39 202.44 1.45 0.54 0.027 
CLEC2L 25.04 36.37 1.45 0.54 0.044 
APPL2 34.53 50.06 1.45 0.54 0.005 
ATP5J2 292.23 423.59 1.45 0.54 0.017 
A930011O12RIK 45.64 66.00 1.45 0.53 0.036 
RPS24 269.31 388.35 1.44 0.53 0.030 
HRH3 24.45 35.14 1.44 0.52 0.033 
RPL41 848.48 1217.59 1.44 0.52 0.023 
C1QA 50.87 72.50 1.43 0.51 0.033 
COX7A2 217.13 302.69 1.39 0.48 0.027 
Down-regulated Genes in Hippocampus 
GPR17 10.45 3.14 0.30 -1.73 0.005 
C1QL1 11.86 3.95 0.33 -1.59 0.005 
FOS 9.35 4.12 0.44 -1.18 0.005 
C1QL2 21.58 10.33 0.48 -1.06 0.005 
SEMA5A 17.15 8.97 0.52 -0.94 0.005 
PDYN 13.53 7.15 0.53 -0.92 0.005 
CASKIN2 8.72 4.63 0.53 -0.92 0.005 
SOX10 19.36 10.46 0.54 -0.89 0.005 
ABHD2 25.40 14.14 0.56 -0.85 0.005 
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KCNG1 16.92 9.44 0.56 -0.84 0.005 
PROX1 18.99 10.62 0.56 -0.84 0.005 
PAQR9 19.64 11.04 0.56 -0.83 0.005 
ADD2 47.62 27.47 0.58 -0.79 0.005 
NEUROD1 15.21 8.88 0.58 -0.78 0.009 
SLC29A4 20.95 12.27 0.59 -0.77 0.005 
ZMAT5 60.85 35.73 0.59 -0.77 0.005 
DUSP18 12.57 7.41 0.59 -0.76 0.005 
TNR 20.98 12.53 0.60 -0.74 0.005 
NPTX1 224.34 136.63 0.61 -0.72 0.005 
FRZB 12.51 7.67 0.61 -0.71 0.012 
KLHL3 11.12 6.84 0.62 -0.70 0.039 
KLF10 11.06 6.81 0.62 -0.70 0.012 
NAPEPLD 11.43 7.10 0.62 -0.69 0.009 
NR4A3 22.92 14.28 0.62 -0.68 0.005 
ERF 14.87 9.27 0.62 -0.68 0.005 
SLC8A2 113.05 70.58 0.62 -0.68 0.005 
MAL 116.49 72.92 0.63 -0.68 0.005 
JPH1 12.87 8.06 0.63 -0.68 0.005 
PLCL1 9.31 5.85 0.63 -0.67 0.005 
SLIT3 15.84 10.03 0.63 -0.66 0.005 
DOC2B 27.24 17.38 0.64 -0.65 0.005 
MYCL 13.32 8.56 0.64 -0.64 0.017 
POLR2A 25.17 16.19 0.64 -0.64 0.005 
NOS1 11.49 7.41 0.64 -0.63 0.012 
JUN 46.65 30.56 0.65 -0.61 0.005 
TMEFF2 41.10 27.04 0.66 -0.60 0.005 
CAMK1D 57.15 37.90 0.66 -0.59 0.005 
TMEM178B 14.37 9.60 0.67 -0.58 0.039 
EFNB3 75.07 50.18 0.67 -0.58 0.005 
LHFPL2 12.53 8.44 0.67 -0.57 0.017 
CCND2 21.85 14.74 0.67 -0.57 0.009 
SLC44A1 39.04 26.34 0.67 -0.57 0.012 
GRIN2B 11.47 7.74 0.68 -0.57 0.020 
ORMDL3 49.03 33.26 0.68 -0.56 0.005 
IGFBP2 84.14 57.15 0.68 -0.56 0.020 
SYNRG 19.24 13.12 0.68 -0.55 0.012 
ARC 49.28 33.68 0.68 -0.55 0.012 
9830001H06RIK 9.63 6.61 0.69 -0.54 0.009 
KBTBD11 36.53 25.15 0.69 -0.54 0.005 
SF3A1 21.44 14.78 0.69 -0.54 0.005 
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PNMAL2 133.70 92.39 0.69 -0.53 0.027 
SLC7A14 30.91 21.37 0.69 -0.53 0.017 
MAG 73.06 50.58 0.69 -0.53 0.015 
KCNC3 50.97 35.32 0.69 -0.53 0.012 
PLXNA4 19.51 13.53 0.69 -0.53 0.012 
FOSL2 14.06 9.76 0.69 -0.53 0.015 
FAM163B 84.89 59.00 0.69 -0.52 0.027 
DPF1 28.61 20.06 0.70 -0.51 0.050 
C1QL3 72.48 50.87 0.70 -0.51 0.025 
DOCK10 13.84 9.72 0.70 -0.51 0.023 
SYNPR 62.30 43.85 0.70 -0.51 0.023 
SOWAHA 52.84 37.49 0.71 -0.50 0.033 
SEZ6L 54.75 38.89 0.71 -0.49 0.036 
SEZ6L 54.75 38.89 0.71 -0.49 0.036 
CAMKK1 87.63 62.29 0.71 -0.49 0.017 
RBFOX3 88.29 62.88 0.71 -0.49 0.033 
RBFOX3 88.29 62.88 0.71 -0.49 0.033 
NEK6 19.70 14.04 0.71 -0.49 0.046 
SF3B3 21.82 15.56 0.71 -0.49 0.034 
CSNK1D 63.31 45.53 0.72 -0.48 0.034 
CSNK1D 63.31 45.53 0.72 -0.48 0.034 
ATP8A1 43.01 31.00 0.72 -0.47 0.044 
PRPF8 40.22 29.05 0.72 -0.47 0.036 
HEXIM1 33.50 24.23 0.72 -0.47 0.046 
























Up-regulated Genes in the CC 
IFN Type I and II Signaling Pathway and Defense Pathways for Viral 
Infection 
MX1 131.46 9.16 14.36 3.84 0.004 
XAF1 40.51 2.88 14.09 3.82 0.004 
IFI44L 138.22 11.14 12.41 3.63 0.004 
IFIT1 203.88 19.59 10.41 3.38 0.004 
IFITM3 759.62 83.51 9.10 3.19 0.004 
IFIT3 173.60 19.38 8.96 3.16 0.004 
RSAD2 27.92 3.16 8.84 3.14 0.017 
IFI6 2043.35 231.66 8.82 3.14 0.004 
ISG15 1008.52 119.96 8.41 3.07 0.004 
USP18 37.35 5.41 6.90 2.79 0.009 
BST2 89.42 13.57 6.59 2.71 0.013 
PLSCR1 51.33 8.17 6.28 2.65 0.004 
HERC5 36.48 5.94 6.14 2.62 0.004 
OAS3 48.03 8.19 5.86 2.55 0.004 
STAT1 249.01 72.63 3.43 1.78 0.004 
EIF2AK2 59.52 17.61 3.38 1.76 0.004 
IFIT5 57.97 17.49 3.31 1.73 0.004 
IFIT2 41.82 12.95 3.23 1.69 0.004 
IRF9 185.27 65.98 2.81 1.49 0.004 
ADAR 115.56 52.32 2.21 1.14 0.004 
STAT2 34.46 20.47 1.68 0.75 0.004 
Mitochondria RNA Catabolism 
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CMPK2 29.17 2.21 13.18 3.72 0.004 
PNPT1 23.36 13.54 1.73 0.79 0.004 
Innate Immune Receptor 
DDX58 36.69 7.61 4.82 2.27 0.004 
Associated with IFN Signaling pathway and antiviral response 
HERC6 68.08 8.94 7.61 2.93 0.004 
DTX3L 26.41 6.63 3.98 1.99 0.004 
PARP14 37.21 9.95 3.74 1.90 0.004 
PARP9 52.37 14.18 3.69 1.88 0.004 
SHISA5 105.47 46.69 2.26 1.18 0.004 
PPM1K 49.02 24.16 2.03 1.02 0.004 
LAP3 55.17 31.43 1.76 0.81 0.004 
Down Regulated Genes in Corpus Callosum 
Myelination and Axon Ensheathment 
MBP 343.13 1266.74 0.27 -1.88 0.004 
MOBP 35.70 124.94 0.29 -1.81 0.004 
MAG 16.20 45.68 0.35 -1.50 0.004 
PLP1 338.58 889.86 0.38 -1.39 0.004 
CLDN11 24.98 64.78 0.39 -1.37 0.004 
Nervous System Development 
STMN2 14.50 37.20 0.39 -1.36 0.004 
ZNF488 11.10 22.15 0.50 -1.00 0.004 
IGFBP5 29.92 58.74 0.51 -0.97 0.004 
BIN1 26.69 46.21 0.58 -0.79 0.020 
APLP1 40.69 64.66 0.63 -0.67 0.030 
Metabolism and Ion Transport 
ACBD7 27.01 53.99 0.50 -1.00 0.004 
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TF 30.65 58.15 0.53 -0.92 0.004 
MOXD1 21.09 37.95 0.56 -0.85 0.026 
PDDC1 13.83 23.28 0.59 -0.75 0.044 
PPP3CB 55.01 83.67 0.66 -0.61 0.009 
ALDOC 169.85 252.43 0.67 -0.57 0.047 
Cell Cycle Regulation  
CDK18 14.38 29.99 0.48 -1.06 0.004 
TPPP3 37.02 73.94 0.50 -1.00 0.023 
Table 4.2. Differentially expressed human genes in corpus callosum. The 




























Up-regulated Genes in Hippocampus 
IFN Type I and II  Signaling Pathway 
RSAD2 30.58 1.58 19.38 4.28 0.004 
OAS1 56.58 3.70 15.29 3.93 0.004 
MX1 127.26 10.10 12.60 3.65 0.004 
XAF1 33.61 2.67 12.59 3.65 0.004 
ISG15 1253.22 109.74 11.42 3.51 0.004 
IFIT3 171.27 16.78 10.21 3.35 0.004 
IFIT1 216.92 22.98 9.44 3.24 0.004 
IFITM3 799.77 87.99 9.09 3.18 0.004 
IFI44L 154.03 17.66 8.72 3.12 0.004 
IFI6 2209.14 254.83 8.67 3.12 0.004 
USP18 37.89 4.65 8.15 3.03 0.004 
BST2 77.68 10.10 7.69 2.94 0.004 
PLSCR1 57.33 10.20 5.62 2.49 0.004 
IFI35 37.95 7.24 5.24 2.39 0.004 
OAS3 42.35 8.28 5.11 2.35 0.004 
DDX58 33.66 6.86 4.90 2.29 0.004 
IFI44 153.23 33.75 4.54 2.18 0.004 
HERC5 35.53 8.84 4.02 2.01 0.004 
IFIH1 15.80 3.97 3.98 1.99 0.004 
IRF7 15.48 3.94 3.93 1.98 0.008 
DDX60 23.62 6.03 3.92 1.97 0.004 
TRIM21 14.76 3.91 3.78 1.92 0.008 
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DHX58 19.10 5.10 3.75 1.91 0.004 
TRIM22 16.17 4.60 3.52 1.81 0.004 
IFIT2 36.12 10.84 3.33 1.74 0.004 
STAT1 242.18 74.81 3.24 1.69 0.004 
IFIT5 54.64 16.88 3.24 1.69 0.004 
IRF9 178.46 62.65 2.85 1.51 0.004 
HLA-B 107.24 37.75 2.84 1.51 0.004 
HLA-C 83.03 29.71 2.80 1.48 0.004 
B2M 2577.79 1040.45 2.48 1.31 0.004 
EIF2AK2 53.81 21.85 2.46 1.30 0.004 
ADAR 115.75 50.99 2.27 1.18 0.004 
HLA-A 27.69 12.32 2.25 1.17 0.004 
SAMHD1 25.52 12.48 2.05 1.03 0.004 
IFI16 26.55 14.46 1.84 0.88 0.004 
TRIM62 18.10 10.34 1.75 0.81 0.015 
UBE2L6 106.06 62.48 1.70 0.76 0.004 
ZC3HAV1 13.54 8.77 1.54 0.63 0.046 
STAT2 31.52 20.90 1.51 0.59 0.011 
Norepinephrine Metabolic Process 
EPAS1 19.27 12.10 1.59 0.67 0.020 
LY6E 46.10 11.83 3.90 1.96 0.004 
Abnormal Neural Differentiation  
PARP10 20.33 3.32 6.12 2.61 0.004 
GARS 32.13 19.62 1.64 0.71 0.015 
AGRN 41.67 26.44 1.58 0.66 0.004 
SOX10 265.68 181.98 1.46 0.55 0.029 
Down Regulated Genes in Hippocampus 
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MOBP 17.52 59.88 0.29 -1.77 0.006 
CLDN11 13.43 31.50 0.43 -1.23 0.006 
_SEPT4 7.77 17.54 0.44 -1.17 0.018 
C7orf41 15.48 32.09 0.48 -1.05 0.037 
C4orf27 15.48 32.09 0.48 -1.05 0.037 
MAG 11.75 24.12 0.49 -1.04 0.018 
NPAS4 7.54 15.44 0.49 -1.04 0.015 
ACBD7 12.59 24.65 0.51 -0.97 0.006 
CDK18 9.74 17.44 0.56 -0.84 0.046 
JPH3 114.52 203.17 0.56 -0.83 0.035 
RPS19 882.33 1561.56 0.57 -0.82 0.040 
TF 15.42 26.72 0.58 -0.79 0.035 
IGFBP5 18.06 31.14 0.58 -0.79 0.006 
FGF13 28.51 45.76 0.62 -0.68 0.049 












4.5 Materials and Methods  
4.5.1 Animals, cell transplantation, and HIV-1 infection 
Newborn NOD/SCID/IL2Rγc−/− (NSG, stock No: 005557, The Jackson 
Laboratory, Bar Harbor, ME, USA) mice were bred at the University of 
Nebraska Medical Center (UNMC). P0-1 litters were irradiated with 1 Gy (RS 
2000 X-ray Irradiator, Rad Source Technologies, Inc., Suwanee, GA, USA). 
Pups were intrahepatically injected with 5 × 105 CD34+ HSCs. These mice 
were simultaneously transplanted with 1 × 105 NPCs into the right lateral 
ventricle. Blood samples collected from the facial vein were evaluated by flow 
cytometry starting 8 weeks post-engraftment to monitor expansion of human 
leukocytes. Mice with established human hemato-lymphoid reconstitution were 
intraperitoneally infected with the macrophage-tropic HIV-1 strain ADA 
(HIV-1ADA) and euthanized 6 weeks post infection. Mice characteristics are 
listed in Table 3.1. Animal procedures strictly followed the Institutional Animal 
Care and Use Committee-approved protocols at UNMC. 
 
4.5.2 Flow cytometry 
Blood samples were collected from a facial vein in ethylenediaminetetraacetic 
acid (EDTA)-containing tubes (BD Microtainer, Franklin Lakes, NJ, USA) and 
centrifuged at 300 g for 5 min. Plasma was stored for HIV viral load 
measurements. Blood cells were reconstituted in a buffer of 2% FBS in 
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phosphate buffered saline and incubated with antibodies against human cell 
markers, including CD45+ fluorescein isothiocyanate (FITC), CD3+ Alexa700, 
CD19+ R-phycoerythrin (PE) cyanine 7 (Cy7), CD4+ allophycocyanin (APC), 
CD8+ Brilliant VioletTM 450 (BV450), and CD14+ PE for 30 min at 4°C. 
Information on all of the antibodies are listed in S3 Table. Samples were 
analyzed using a BD LSR2 flow cytometer [182]. Gates were assigned 
according to the appropriate control population. 
 
4.5.3 Virus load in plasma, brain, and spleen 
Viral RNA copies in the murine plasma were determined by quantitative 
real-time polymerase chain reaction (PCR) using a COBAS Amplicor System 
v1.5 kit (Roche Molecular Diagnostics, Pleasanton, CA, USA). Spleen and 
brain tissue section samples were analyzed for HIV-1 p24 protein staining. 
Expression of HIV-1 group-specific antigen (gag) RNA in brain tissues were 
analyzed by reverse transcription (RT)-PCR with previously published primers 
and probes [192]. Briefly, cortex and striatum from three HIV-infected dual 
reconstituted mice and three control dual reconstituted mice were 
micro-dissected and transferred to 700 µl QIAzol solution (QIAGEN, Valencia, 
CA, USA) for RNA isolation using an RNeasy Mini kit (QIAGEN, Valencia, CA, 
USA). A Verso cDNA synthesis kit (Thermo Fisher Scientific, Grand Island, 
NY, USA) prepared cDNA according to the manufacturer’s instructions. For the 
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first round of conventional PCR, we used the following primers: sense 5’ 
TCAGCCCAGAAGTAATACCCATGT 3’ and antisense 5’ 
TGCTATGTCAGTTCCCCTTGGTTCTCT 3’. The PCR settings were as 
follows: 94°C for 3 min, 15 cycles of 94°C for 30 sec, 55°C for 30 sec, and 72°C 
for 1 min. The product of the first PCR was subsequently used as a template in 
the second semi-nested real-time PCR amplification performed on the ABI 
StepOne Plus real-time PCR machine (Applied Biosystems, MA, USA) using 
TaqMan detection chemistry. The primers and probe used for the second PCR 
were: sense 5’ TCAGCCCAGAAGTAATACCCATGT 3’, antisense 5’ 
CACTGTGTTTAGCATGGTGTTT 3’, and TaqMan probe 
FAM-ATTATCAGAAGGAGCCACCCCACAAGA-TAMRA. The real-time PCR 
settings were as follows: 50°C for 2 min, 95°C for 10 min, 45 cycles of 95°C for 
15 sec, and 60°C for 1 min. ACH2 cells (8 × 105) containing one integrated 
copy of HIV-1 per cell were used in triplicate as standards, with cell and HIV 
copy numbers ranging in serial 10-fold dilutions from 105 to 
102 deoxyribonucleic acid (DNA) copies/reaction. 
 
4.5.4 Immunohistochemistry 
Brain tissue was cut sagittally for both the left and right hemispheres, fixed with 
4% paraformaldehyde for 24 hours at 4°C, and then embedded in paraffin. 
Paraffin-embedded 5-m thick tissue sections were processed with Declere 
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Solution (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s 
instructions. Tissue was blocked with 10% normal goat serum in Tris-buffered 
saline and 0.05% Tween 20 (TBST) for 45 min and then incubated with mouse 
(ms) anti-human GFAP (1:200; Abcam, Cambridge, MA, USA), ms anti-human 
nuclear antigen (1:200; Millipore, Billerica, MA, USA), ms anti-human 
cytoplasmic marker (1:1000; STEMCELL, Mountain View, Canada), ms 
anti-HIV-1 p24 (1:10; Dako, Carpinteria, CA, USA), ms anti-HLA-DR (1:500; 
Dako, Carpinteria, CA, USA), ms anti-CD163 (1:50; Thermo Scientific, Denver, 
CO, USA), rabbit (rb) anti-GFAP (1:1000; Dako, Carpinteria, CA, USA), and rb 
anti-human CD4 (1:500; Abcam, Cambridge, MA, USA). Secondary antibodies 
were goat anti-ms and goat anti-rb immunoglobulin G (IgG) horseradish 
peroxidase (HRP; Dako, Carpinteria, CA, USA). Bright field images were 
captured and photographed using 20× and 100× objectives on a Nuance 
Multispectral Tissue Imaging system (CRi, Wobum, MA). Immunostained 
sections were scanned using a high-resolution scanner (Ventana Medical 
Systems, Inc., Oro Valley, AZ, USA). DEFINIENS Tissue Studio® software 
(Definiens AG, Munich, Germany) was used to analyze the brain sections 
stained for human glial and immune cells. None of human-specific antibodies 




For immunofluorescent staining of paraffin-embedded tissue, sections were 
processed and blocked as described above. Ms anti-human GFAP (1:200; 
Abcam, Cambridge, MA, USA), ms anti-human nuclei (1:200; Millipore, 
Billerica, MA, USA), rb anti-GFAP (1:1000; Dako, Carpinteria, CA, USA), and 
rb anti-Oligo2 (1:500; PhosphoSolutions, Aurora, CO, USA) were applied. For 
immunofluorescent characterization of cultivated NPC, ms anti-human GFAP 
(1:200; Abcam, Cambridge, MA, USA), ms anti-MAP2 (1:200; Santa Cruz, 
Santa Cruz, CA, USA), ms anti-glutamic acid decarboxylase 67 (GAD67; 
1:500; Millipore, Billerica, MA, USA), rb anti-nestin (1:200; Millpore, Billerica, 
MA, USA), and rb anti-Tuj-1 (1:500; Biolegend, San Diego, CA, USA) were 
applied. Secondary antibodies were goat anti-ms IgG Alexa 488 (1:00; 
Invitrogen, Grand Island, NY, USA), goat anti-ms IgG Alexa 594 (1:00; 
Invitrogen, Grand Island, NY, USA), goat anti-rb IgG Alexa 488 (1:100; 
Invitrogen, Grand Island, NY, USA), and goat anti-ms IgG Alexa 594 (1:00; 
Invitrogen, Grand Island, NY, USA). A Leica DM6 system (Leica 
Microsystems, Wetzlar, Germany) and a Zeiss LSM510 confocal system (Carl 
Zeiss Microscopy GmbH, Jena, Germany) were also used for 
immunofluorescent imaging. The intensity of illumination and the position of 
the sub-region on the microscope were consistent across all images.  
 
4.5.6 RNA isolation and next generation sequencing 
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Left hemispheres of the reconstituted mouse brains were preserved in 
RNALater (Invitrogen, Grand Island, NY, USA). The corpus callosum and 
hippocampus from three HIV-infected dual reconstituted mice, three control 
dual reconstituted mice, and three non-manipulated NSG mice were 
micro-dissected and transferred to 700 µl of QIAzol solution (QIAGEN, 
Valencia, CA, USA) for RNA isolation using an RNeasy Mini kit (QIAGEN, 
Valencia, CA, USA). After RNA integrity was analyzed, samples were deep 
sequenced using 100 bp/read, up to 40 million reads/sample using an Illumina 
HiSeq 2500 Sequence Analyzer (Illumina, Inc., San Diego, CA, USA). For both 
the hippocampus and corpus callosum, we compared the control samples 
(NSG1–3) to the humanized mouse samples (865, 866, 870), and the 
humanized mouse samples to the humanized mouse samples with HIV (862, 
868, 869). The reads were mapped to the mm10 mouse genome and the 
mouse transcriptome. A third comparison was also made whereby humanized 
mouse samples (865, 866, 870) were compared with humanized mouse 
samples with HIV (862, 868, 869), but mapped to the hg19 human database. 
For both tissues, we collected the unmapped reads, which did not map to the 
mouse genome, and remapped them to the human genome. This was done in 
order to see what human genes were expressed in these tissues. The cuffdiff 
algorithm was used to identify differentially expressed genes; all significant 
genes were reported with an FDR adjusted p-value of 5% for all cuffdiff 
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comparisons. Cuffdiff was specifically used because it normalizes the 
expression values and protects against overdispersion so that the values fit 
into a normalized bell curve [200]. The number of total reads and alignment 
results are shown in S2 Table.  
 
4.5.7 Macrophage and human fetal astrocyte co-culture 
Human monocytes were isolated by leukopheresis from HIV-1/2 and hepatitis 
seronegative donors. Human monocytes (2 ×105) were seeded in the inserts of 
24-well transwell plates with a pore size of 0.4 µm. (Corning Costar, Corning, 
NY, USA). Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen, Grand 
Island, NY, USA) with 10% heat-inactivated pooled human serum, 2 mM 
L-glutamine, 50 µg/ml gentamicin, 10 µg/ml ciprofloxacin, and macrophage 
colony-stimulating factor (MCSF) enriched conditioned medium maintained at 
37°C in a 5% CO2 incubator was used [227]. On day 7, differentiated 
monocyte-derived macrophages (MDM) were infected with HIV-1ADA 
(multiplicity of infection (MOI) = 0.01) for 12 hours. Infected macrophages were 
maintained in the DMEM medium containing 10% heat-inactivated pooled 
human serum, 2 mM L-glutamine, 50 µg/ml gentamicin, and 10 µg/ml 
ciprofloxacin for another 6 days before the inserts were transferred to wells 
with astrocytes at the bottom. Human fetal astrocytes (HFA) were isolated and 
cultured from fetal donors as previously described [228]. HFA (5 ×105) were 
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seeded at the bottom of 24-well transwell plates and maintained in DMEM/F12 
(Invitrogen, Grand Island, NY, USA) containing 10% FBS and antibiotics. 
Supernatants from HIV-1-infected and control MDM cultures were collected at 
6 days, 4 days, and 2 days before co-culture of MDM and astrocytes. 
Supernatants from the transwell system were collected at 24 hours, 3 days, 5 
days, and 7 days after co-culture. 
 
4.5.8 IFN-β enzyme-linked immunosorbent assay (ELISA) 
IFN-β was measured in the supernatants of astrocytes (Ast baseline), a 
co-culture of astrocytes and control macrophages (Ctl-Ast-MDM), a co-culture 
of astrocytes and HIV-infected macrophages (HIV-Ast-MDM), HIV-infected 
macrophages (HIV-MDM baseline), and control macrophages (Ctl-MDM 
baseline) using the Human IFN-β bioluminescent ELISA kit (InVivoGen, San 
Diego, CA, USA) according to the manufacturer’s protocol. 
 
4.5.9 RT-PCR for selected human and mouse transcripts 
First-strand cDNA was prepared from corpus callosum and hippocampus 
using the same method described above. For both the hippocampus and 
corpus callosum, we compared the control humanized mouse samples (865, 
866, 870, 871) to the humanized mouse samples with HIV (861, 862, 864, 867, 
868, 869).  The catalog numbers of all TagMan® real-time PCR assays from 
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Life Technologies are as listed below: hu-STAT1 (Hs01013996_m1), 
hu-STAT2 (Hs01013123_m1), hu-IRF9 (Hs00196051_m1), hu-MX1 
(Hs00895609_m1), hu-ISG15 (Hs01921425_s1), hu-CMPK2 
(Hs01013364_m1), hu-IFI6 (Hs00242571_m1), hu-MBP (Hs00921945_m1), 
hu-ZNF488 (Hs00289045_s1), hu-GAPDH (Hs03929097_g1), ms-MX1 
(Mm00487796_m1), ms-MBP (Mm01266402_m1), ms-GAPDH 
(Mm999999_g1). The real-time PCR settings were as follows: 50°C for 2 min, 
95°C for 10 min, 40 cycles of 95°C for 15 sec, and 60°C for 1 min. All real-time 
assays were carried out with an Applied 
Biosystems® StepOnePlus Real-Time PCR Systems. The fold change in 
expression of each target gene mRNA relative to GAPDH between the HIV+ 
group and the control group was determined by using threshold cycle (Ct) and 



















CHAPTER - 5 












5.1 Summary  
Despite of the extensive application of potent antiretroviral therapies, HAND 
remains prevalent in nearly 30% HIV-infected individuals. The underlying 
neuropathology is rapidly evolving in the era of cART. Translational animal 
models remain essential for thorough understanding of the patho-biological 
mechanism of HAND, and more importantly for investigating HIV reservoirs in 
the central nervous system, as comprehensive research cannot be carried out 
in a controlled and reproducible manner on humans. Although the non-human 
primate models, HIV-infected humanized mouse models have been 
characterized extensively for their ability to recapitulate the human immune 
response against HIV, and been applied widely to test the efficacy of 
therapeutic approaches, they still remain insufficient to assess the complex 
neuroimmune crosstalk during chronic HIV infection, and to investigate the 
sites where virus hiding behind blood-brain barrier for the eventual goal of viral 
eradication. Due to these unmet needs, a new mouse model with combined 
human immune system and glia cells reconstitution was proposed to study HIV 
neuropathogenesis. 
Innovation of the work is highlighted in Chapter 3, we introduced the 
development of a dual reconstituted chimeric mouse model contained both a 
human immune system and human glia (primarily astrocyte and 
oligodendrocyte lineage) in the brain. As mentiond above, studies of innate 
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glial cell responses after progressive human HIV-1 infection are hindered due 
to the paucity of relevant small-animal models of human disease. To overcome 
this limitation, we reported a mouse model with dual humanized glial 
components in the brain and human immune system in the periphery. We 
transplanted newborn NSG mice both with human NPCs and HSCs in the 
lateral ventricle and in the liver respectively. Human cells repopulated the 
white matter and periventricular mouse brain regions in an anatomically 
symmetrical manner. These human cells were later revealed by 
immunohistochemistry as astrocyte and oligodendrocyte lineages. The highest 
level of reconstitution was in corpus callosum and periventricular region 
(around 70-80% of total nucleated cells), with relatively low levels in other 
regions like frontal cortex, striatum and brain stem (Around 10-20% of total 
nucleated cells). RNA sequencing was applied to examine the influence of 
human cell engraftment on the mouse transcriptional profile in selected brain 
regions. Human glial engraftment induced modest yet extensive transcriptional 
changes associated with multiple biological processes, including synaptic 
transportation, angiogenesis, and axon growth, ion channel activities, 
compared to non-reconstituted mice. 
Uniqueness of the study is shown in Chapter 4, where we investigated the 
pathological and molecular changes in this dual reconstituted mouse model 
after being infected with macrophage-tropic HIV-1ADA. The Immune analyses of 
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these HIV-1-infected mice showed meningeal and perivascular infiltration by 
human HLA-DR+ cells and surveillance by activated immune cells in brain 
tissue. The molecular mechanisms underlying species-specific virus-immune 
system-brain tissue interactions were identified by deep RNA sequencing. In 
comparison with uninfected mice, infected human glia-containing brain 
samples exhibited unique expression of 45 and 56 human genes in the 
hippocampus and corpus callosum respectively. These transcriptional 
alterations were linked to IFN type 1 and 2 signaling pathways (STAT1, 2, 
IRF9, MX1, ISG15, IFI6, CMPK2) and a range of host antiviral responses. 
Differentially expressed mouse genes in the hippocampus reflected tissue 
remodeling while down-regulated human genes were linked to altered cell 
growth, glial cytoskeleton reorganization, oligodendrocyte differentiation and 
myelin ensheathment (MBP, MOBP, PLP1, MAG and ZNF488). The results 
surprisingly overlapped with the disease profile observed by others in human 
HIV-1 encephalitic brains. This new model provided a promising future for 
study of human-specific viral-glial interactions and discovery of new 
therapeutics targets for HIV-1 nervous system infection. 
 
5.2 Further needed refinements of the dual humanized mice 
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Despite several advantages of such a chimeric mouse model in studying HIV 
neuropathogenesis and nervous system reservoirs, limitations do exist in 
following aspects. 
 First, similar to other animal models requiring engraftment of donor cell or 
tissues, differences in each manipulation and heterogeneity existing 
throughout donors and recipients resulted in inconsistencies of human cell 
repopulation between animals. These features can confound the interpretation 
of glial reactions to viral infections and responses to therapies among each 
individual. One practical strategy is to standardize the procedures by utilizing 
an automatic stereotaxic injection platform to perform human NPCs 
transplantation, instead of manual injection.  Another potential strategy to 
overcome this limitation is to utilize the technique of induced-pluripotent stem 
cells (iPSCs) to generate homogenous clones of progenitor cells for astrocytes 
as introduced in the previous study [229].  Additionally, prudent statistical 
analyses are necessary for reaching significant conclusions when using this 
model for quantitative research. For instance, when we were analyzing the 
number of human astrocytes in infected and control mice, up to 50 animals and 
200 tissue samples were analyzed by the non-biased image studio to compare 
human astrocyte numbers between groups.   
 Additionally, productive infection of astrocytes has not been observed in 
this in vivo model. Although infection of astrocytes by HIV is highly restricted 
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[113], it has been hypothesized astrocytes are potential reservoirs in the CNS. 
Future efforts on isolating human astrocytes from the chimeric mouse brain 
and examining the viral genome ex vivo utilizing more sensitive methods would 
be very helpful in testing the hypothesis. The development of single-cell 
resolution sequencing methods is also encouraging in differentiating 
astrocyte-specific molecular signatures in response to chronic HIV infection 
[230].   
Thirdly, considerable work is underway to achieve the goal of human 
microglial reconstitution, including identifying the human microglia progenitors 
during primitive hematopoiesis, and to generating a mouse brain 
microenvironment permissive to human microglia survival and development 
the reconstitution of human microglia.  
 
5.3 Applications of dual humanized mice model in development of 
diagnostic and therapeutics for NeruoAIDS and infections of other 
pathogens  
There are extensive possibilities for future applications of the dual humanized 
mouse model in the development of diagnostic and therapeutic approaches for 
NeuroAIDS. As reviewed in the Chapter – 1, the old HIVE model has been 
extensively applied to test the delivery system of antiretroviral drugs and 
adjunctive therapies. This new model with sustained hematopoiesis and 
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human glial components will promote longitudinal studies of the efficacy of 
cART in protecting human glial cells. In addition, recent studies reported that 
blockage of type-I interferon signaling can restore immune function and reduce 
HIV-1 reservoirs in the periphery during chronic infection [231-233]. The 
human specific transcriptional profiles revealed in the infected dual humanized 
mice brains also raised the concern about the role of type-I IFN signaling in the 
CNS HIV infection, whether it is beneficial or detrimental? The future 
application of the dual humanized mouse model will help to address this 
question. 
Besides, the dual humanized mice will be benefit the studies of other 
neurotropic pathogens that target astrocytes and neural progenitor lineages, 
such as John Cunningham virus (JCV), Human cytomegalovirus (HCMV), 
Herpes simplex virus (HSV) et al., regarding their neuropathogenesis, latency, 











1. HIV, C., Aids. Medical Care, 2012. 916: p. 874-7720. 
2. Autran, B., et al., Positive effects of combined antiretroviral therapy on 
CD4+ T cell homeostasis and function in advanced HIV disease. 
Science, 1997. 277(5322): p. 112-116. 
3. Fauci, A.S. and G.K. Folkers, Toward an AIDS-free generation. Jama, 
2012. 308(4): p. 343-344. 
4. Simioni, S., et al., Cognitive dysfunction in HIV patients despite 
long-standing suppression of viremia. Aids, 2010. 24(9): p. 1243-1250. 
5. Heaton, R.K., et al., HIV-associated neurocognitive disorders before 
and during the era of combination antiretroviral therapy: differences in 
rates, nature, and predictors. Journal of neurovirology, 2011. 17(1): p. 
3-16. 
6. Heaton, R., et al., HIV-associated neurocognitive disorders persist in 
the era of potent antiretroviral therapy CHARTER Study. Neurology, 
2010. 75(23): p. 2087-2096. 
7. Ammassari, A., et al., Depressive symptoms, neurocognitive 
impairment, and adherence to highly active antiretroviral therapy among 
HIV-infected persons. Psychosomatics, 2004. 45(5): p. 394-402. 
	 141 
8. Koenig, S. and A.S. Fauci, Detection of AIDS virus in macrophages in 
brain tissue from AIDS patients with encephalopathy. Science, 1986. 
233: p. 1089-1094. 
9. Dohgu, S., et al., Human immunodeficiency virus-1 uses the 
mannose-6-phosphate receptor to cross the blood-brain barrier. PLOS 
one, 2012. 7(6): p. e39565. 
10. Persidsky, Y. and H.E. Gendelman, Mononuclear phagocyte immunity 
and the neuropathogenesis of HIV-1 infection. Journal of leukocyte 
biology, 2003. 74(5): p. 691-701. 
11. Eugenin, E.A., et al., Human immunodeficiency virus infection of human 
astrocytes disrupts blood–brain barrier integrity by a gap 
junction-dependent mechanism. Journal of Neuroscience, 2011. 31(26): 
p. 9456-9465. 
12. Toggas, S.M., et al., Central nervous system damage produced by 
expression of the HIV-1 coat protein gpl20 in transgenic mice. Nature, 
1994. 367(6459): p. 188-193. 
13. Jana, A. and K. Pahan, Human immunodeficiency virus type 1 gp120 
induces apoptosis in human primary neurons through redox-regulated 
activation of neutral sphingomyelinase. Journal of Neuroscience, 2004. 
24(43): p. 9531-9540. 
	 142 
14. Nath, A., Human immunodeficiency virus (HIV) proteins in 
neuropathogenesis of HIV dementia. Journal of Infectious Diseases, 
2002. 186(Supplement 2): p. S193-S198. 
15. Li, W., et al., Role of Tat protein in HIV neuropathogenesis. 
Neurotoxicity research, 2009. 16(3): p. 205-220. 
16. Bruce-Keller, A.J., et al., Synaptic transport of human 
immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in 
rat brain. Journal of Neuroscience, 2003. 23(23): p. 8417-8422. 
17. Torres-Muñoz, J., et al., Detection of HIV-1 gene sequences in 
hippocampal neurons isolated from postmortem AIDS brains by laser 
capture microdissection. Journal of Neuropathology & Experimental 
Neurology, 2001. 60(9): p. 885-892. 
18. van Marle, G., et al., Human immunodeficiency virus type 1 Nef protein 
mediates neural cell death: a neurotoxic role for IP-10. Virology, 2004. 
329(2): p. 302-318. 
19. Bsibsi, M., et al., Broad expression of Toll-like receptors in the human 
central nervous system. Journal of Neuropathology & Experimental 
Neurology, 2002. 61(11): p. 1013-1021. 
20. Farina, C., F. Aloisi, and E. Meinl, Astrocytes are active players in 
cerebral innate immunity. Trends in immunology, 2007. 28(3): p. 
138-145. 
	 143 
21. Gehrmann, J., R.B. Banati, and G.W. Kreutzberg, Microglia in the 
immune surveillance of the brain: human microglia constitutively 
express HLA-DR molecules. Journal of neuroimmunology, 1993. 48(2): 
p. 189-198. 
22. Paolicelli, R.C., et al., Synaptic pruning by microglia is necessary for 
normal brain development. science, 2011. 333(6048): p. 1456-1458. 
23. Tremblay, M.-È. and A.K. Majewska, A role for microglia in synaptic 
plasticity? Communicative & integrative biology, 2011. 4(2): p. 220-222. 
24. Perry, V.H., J.A. Nicoll, and C. Holmes, Microglia in neurodegenerative 
disease. Nature Reviews Neurology, 2010. 6(4): p. 193-201. 
25. Streit, W.J., M.B. Graeber, and G.W. Kreutzberg, Functional plasticity of 
microglia: a review. Glia, 1988. 1(5): p. 301-307. 
26. Hemachudha, T., et al., Myelin basic protein as an encephalitogen in 
encephalomyelitis and polyneuritis following rabies vaccination. New 
England Journal of Medicine, 1987. 316(7): p. 369-374. 
27. Ozawa, H., et al., Acute disseminated encephalomyelitis associated 
with poliomyelitis vaccine. Pediatric neurology, 2000. 23(2): p. 177-179. 
28. Whitley, R.J., Viral encephalitis. New England Journal of Medicine, 
1990. 323(4): p. 242-250. 
29. He, J., et al., CCR3 and CCR5 are co-receptors for HIV-1 infection of 
microglia. Nature, 1997. 385(6617): p. 645. 
	 144 
30. Sørensen, L.N., et al., TLR2 and TLR9 synergistically control herpes 
simplex virus infection in the brain. The Journal of Immunology, 2008. 
181(12): p. 8604-8612. 
31. Schifitto, G., et al., Memantine and HIV-associated cognitive 
impairment: a neuropsychological and proton magnetic resonance 
spectroscopy study. Aids, 2007. 21(14): p. 1877-1886. 
32. Masliah, E., N. Ge, and L. Mucke, Pathogenesis of HIV-1 associated 
neurodegeneration. Critical Reviews™ in Neurobiology, 1996. 10(1). 
33. Kumar, A.M., et al., Human immunodeficiency virus type 1 RNA Levels 
in different regions of human brain: Quantification using real-time 
reverse transcriptase–polymerase chain reaction. Journal of 
neurovirology, 2007. 13(3): p. 210-224. 
34. Gray, F., Neuronal apoptosis does not correlate with dementia in HIV 
infection but is related to microglial activation and axonal damage. 
Neuropathol Appl Neurobiol, 1999. 25: p. 123-133. 
35. Devlin, K.N., et al., Neurocognitive effects of HIV, hepatitis C, and 
substance use history. Journal of the International Neuropsychological 
Society: JINS, 2012. 18(1): p. 68. 
36. Alexaki, A., Y. Liu, and B. Wigdahl, Cellular reservoirs of HIV-1 and their 
role in viral persistence. Current HIV research, 2008. 6(5): p. 388-400. 
	 145 
37. Thompson, K.A., et al., Brain cell reservoirs of latent virus in 
presymptomatic HIV-infected individuals. The American journal of 
pathology, 2011. 179(4): p. 1623-1629. 
38. Spillantini, M.G., et al., α-Synuclein in Lewy bodies. Nature, 1997. 
388(6645): p. 839-840. 
39. Lashley, T., et al., Review: an update on clinical, genetic and 
pathological aspects of frontotemporal lobar degenerations. 
Neuropathology and applied neurobiology, 2015. 41(7): p. 858-881. 
40. Polymeropoulos, M.H., et al., Mutation in the α-synuclein gene identified 
in families with Parkinson's disease. science, 1997. 276(5321): p. 
2045-2047. 
41. Salminen, A., et al., Inflammation in Alzheimer's disease: amyloid-β 
oligomers trigger innate immunity defence via pattern recognition 
receptors. Progress in neurobiology, 2009. 87(3): p. 181-194. 
42. McGeer, P.L. and E.G. McGeer, Inflammation and neurodegeneration 
in Parkinson's disease. Parkinsonism & related disorders, 2004. 10: p. 
S3-S7. 
43. Morgan, D., et al., Aβ peptide vaccination prevents memory loss in an 
animal model of Alzheimer's disease. Nature, 2000. 408(6815): p. 
982-985. 
	 146 
44. Schneeberger, A., L. Tierney, and M. Mandler, Active immunization 
therapies for Parkinson's disease and multiple system atrophy. 
Movement Disorders, 2016. 31(2): p. 214-224. 
45. Benner, E.J., et al., Therapeutic immunization protects dopaminergic 
neurons in a mouse model of Parkinson's disease. Proceedings of the 
National Academy of Sciences of the United States of America, 2004. 
101(25): p. 9435-9440. 
46. Buchbinder, S.P., et al., Efficacy assessment of a cell-mediated 
immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, 
placebo-controlled, test-of-concept trial. The Lancet, 2008. 372(9653): 
p. 1881-1893. 
47. Benarroch, E.E., Neuron-astrocyte interactions: partnership for normal 
function and disease in the central nervous system. Mayo Clin Proc, 
2005. 80(10): p. 1326-38. 
48. Ransohoff, R.M. and M.A. Brown, Innate immunity in the central 
nervous system. The Journal of clinical investigation, 2012. 122(4): p. 
1164-1171. 
49. Pardridge, W.M., The blood-brain barrier: bottleneck in brain drug 
development. NeuroRx, 2005. 2(1): p. 3-14. 
50. Baseri, B., et al., Activation of signaling pathways following localized 
delivery of systemically administered neurotrophic factors across the 
	 147 
blood–brain barrier using focused ultrasound and microbubbles. 
Physics in medicine and biology, 2012. 57(7): p. N65. 
51. Gabathuler, R., Approaches to transport therapeutic drugs across the 
blood–brain barrier to treat brain diseases. Neurobiology of disease, 
2010. 37(1): p. 48-57. 
52. Meairs, S. and A. Alonso, Ultrasound, microbubbles and the blood–
brain barrier. Progress in biophysics and molecular biology, 2007. 
93(1): p. 354-362. 
53. Dash, P.K., et al., Loss of neuronal integrity during progressive HIV-1 
infection of humanized mice. Journal of Neuroscience, 2011. 31(9): p. 
3148-3157. 
54. Hall, J., et al., Delivery of therapeutic proteins via extracellular vesicles: 
review and potential treatments for Parkinson’s disease, glioma, and 
schwannoma. Cellular and molecular neurobiology, 2016. 36(3): p. 
417-427. 
55. Pathan, S.A., et al., CNS drug delivery systems: novel approaches. 
Recent patents on drug delivery & formulation, 2009. 3(1): p. 71-89. 
56. Mallapragada, S.K., et al., Enabling nanomaterial, nanofabrication and 
cellular technologies for nanoneuromedicines. Nanomedicine: 
Nanotechnology, Biology and Medicine, 2015. 11(3): p. 715-729. 
	 148 
57. Brynskikh, A.M., et al., Macrophage delivery of therapeutic nanozymes 
in a murine model of Parkinson’s disease. Nanomedicine, 2010. 5(3): p. 
379-396. 
58. Nowacek, A. and H.E. Gendelman, NanoART, neuroAIDS and CNS 
drug delivery. Nanomedicine, 2009. 4(5): p. 557-574. 
59. Biju, K., et al., Macrophage-mediated GDNF delivery protects against 
dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's 
disease. Molecular Therapy, 2010. 18(8): p. 1536-1544. 
60. Eggert, D., et al., Neuroprotective activities of CEP-1347 in models of 
neuroAIDS. The journal of immunology, 2010. 184(2): p. 746-756. 
61. Batrakova, E.V. and M.S. Kim, Using exosomes, naturally-equipped 
nanocarriers, for drug delivery. Journal of Controlled Release, 2015. 
219: p. 396-405. 
62. Combs, C.K., et al., Inflammatory mechanisms in Alzheimer's disease: 
inhibition of β-amyloid-stimulated proinflammatory responses and 
neurotoxicity by PPARγ agonists. Journal of Neuroscience, 2000. 20(2): 
p. 558-567. 
63. Aguzzi, A., B.A. Barres, and M.L. Bennett, Microglia: scapegoat, 
saboteur, or something else? Science, 2013. 339(6116): p. 156-161. 
	 149 
64. Kim, Y.S. and T.H. Joh, Microglia, major player in the brain 
inflammation: their roles in the pathogenesis of Parkinson's disease. 
Experimental & molecular medicine, 2006. 38(4): p. 333. 
65. Shih, A.Y., et al., Policing the police: astrocytes modulate microglial 
activation. Journal of Neuroscience, 2006. 26(15): p. 3887-3888. 
66. Heneka, M.T., M.P. Kummer, and E. Latz, Innate immune activation in 
neurodegenerative disease. Nature Reviews Immunology, 2014. 14(7): 
p. 463-477. 
67. Wilson, E.H., W. Weninger, and C.A. Hunter, Trafficking of immune 
cells in the central nervous system. The Journal of clinical investigation, 
2010. 120(5): p. 1368-1379. 
68. Kurkowska-Jastrzebska, I., et al., MHC class II positive microglia and 
lymphocytic infiltration are present in the substantia nigra and striatum 
in mouse model of Parkinson's disease. Acta neurobiologiae 
experimentalis, 1999. 59(1): p. 1-8. 
69. Rivest, S., Regulation of innate immune responses in the brain. Nature 
Reviews Immunology, 2009. 9(6): p. 429-439. 
70. Skaper, S.D., L. Facci, and P. Giusti, Mast cells, glia and 
neuroinflammation: partners in crime? Immunology, 2014. 141(3): p. 
314-327. 
	 150 
71. Popovich, P.G. and E.E. Longbrake, Can the immune system be 
harnessed to repair the CNS? Nature Reviews Neuroscience, 2008. 
9(6): p. 481-493. 
72. Nowacek, A., L.M. Kosloski, and H.E. Gendelman, Neurodegenerative 
disorders and nanoformulated drug development. Nanomedicine, 2009. 
4(5): p. 541-555. 
73. Williams, D.W., et al., Monocyte maturation, HIV susceptibility, and 
transmigration across the blood brain barrier are critical in HIV 
neuropathogenesis. Journal of leukocyte biology, 2012. 91(3): p. 
401-415. 
74. Anderson, E.R., H.E. Gendelman, and H. Xiong, Memantine protects 
hippocampal neuronal function in murine human immunodeficiency 
virus type 1 encephalitis. Journal of Neuroscience, 2004. 24(32): p. 
7194-7198. 
75. Maroney, A.C., et al., Cep-1347 (KT7515), a semisynthetic inhibitor of 
the mixed lineage kinase family. Journal of Biological Chemistry, 2001. 
276(27): p. 25302-25308. 
76. Falsig, J., et al., Specific modulation of astrocyte inflammation by 
inhibition of mixed lineage kinases with CEP-1347. The Journal of 
Immunology, 2004. 173(4): p. 2762-2770. 
	 151 
77. Hidding, U., et al., The c-Jun N-terminal kinases in cerebral microglia: 
immunological functions in the brain. Biochemical pharmacology, 2002. 
64(5): p. 781-788. 
78. Handley, M.E., et al., Expression and function of mixed lineage kinases 
in dendritic cells. International immunology, 2007. 19(8): p. 923-933. 
79. Ahmed, R.A.M., et al., c-Jun N-terminal kinases inhibitor suppresses 
the TNF-α induced MCP-1 expression in human umbilical vein 
endothelial cells. Endocrine, 2009. 35(2): p. 184-188. 
80. Young, S.K. and P.G. Arndt, c-Jun NH2-terminal kinase regulates 
lipopolysaccharide-induced pulmonary mononuclear cell recruitment via 
CCL2. Experimental lung research, 2009. 35(8): p. 682-700. 
81. Sui, Z., et al., Inhibition of mixed lineage kinase 3 prevents HIV-1 
Tat-mediated neurotoxicity and monocyte activation. The Journal of 
Immunology, 2006. 177(1): p. 702-711. 
82. Lotharius, J., et al., Progressive degeneration of human mesencephalic 
neuron-derived cells triggered by dopamine-dependent oxidative stress 
is dependent on the mixed-lineage kinase pathway. Journal of 
Neuroscience, 2005. 25(27): p. 6329-6342. 
83. Apostol, B.L., et al., CEP-1347 reduces mutant huntingtin-associated 
neurotoxicity and restores BDNF levels in R6/2 mice. Molecular and 
Cellular Neuroscience, 2008. 39(1): p. 8-20. 
	 152 
84. Investigators, P.S.G.P., Mixed lineage kinase inhibitor CEP-1347 fails 
to delay disability in early Parkinson disease. Neurology, 2007. 69(15): 
p. 1480-1490. 
85. McGeer, P.L., et al., Rate of cell death in parkinsonism indicates active 
neuropathological process. Annals of neurology, 1988. 24(4): p. 
574-576. 
86. Dunnett, S.B. and A. Björklund, Prospects for new restorative and 
neuroprotective treatments in Parkinson's disease. Nature, 1999. 399: 
p. A32-A39. 
87. Kaneko, M., et al., Neurotrophic 3, 9-bis [(alkylthio) methyl]-and-bis 
(alkoxymethyl)-K-252a derivatives. Journal of medicinal chemistry, 
1997. 40(12): p. 1863-1869. 
88. Marker, D.F., et al., The new small-molecule mixed-lineage kinase 3 
inhibitor URMC-099 is neuroprotective and anti-inflammatory in models 
of human immunodeficiency virus-associated neurocognitive disorders. 
Journal of Neuroscience, 2013. 33(24): p. 9998-10010. 
89. Zhang, G., et al., The mixed lineage kinase-3 inhibitor URMC-099 
improves therapeutic outcomes for long-acting antiretroviral therapy. 
Nanomedicine: Nanotechnology, Biology and Medicine, 2016. 12(1): p. 
109-122. 
	 153 
90. Gnanadhas, D.P., et al., Autophagy facilitates macrophage depots of 
sustained-release nanoformulated antiretroviral drugs. The Journal of 
Clinical Investigation, 2017. 127(3). 
91. Woodward, E. and M. Troedsson, Inflammatory mechanisms of 
endometritis. Equine veterinary journal, 2015. 47(4): p. 384-389. 
92. Dou, H., et al., Macrophage delivery of nanoformulated antiretroviral 
drug to the brain in a murine model of neuroAIDS. The Journal of 
immunology, 2009. 183(1): p. 661-669. 
93. Duebgen, M., et al., Stem cells loaded with multimechanistic oncolytic 
herpes simplex virus variants for brain tumor therapy. Journal of the 
National Cancer Institute, 2014. 106(6): p. dju090. 
94. Munoz, J.L., et al., Delivery of functional anti-miR-9 by mesenchymal 
stem cell–derived exosomes to glioblastoma multiforme cells conferred 
chemosensitivity. Molecular Therapy—Nucleic Acids, 2013. 2(10): p. 
e126. 
95. Moreland, L.W., et al., Etanercept Therapy in Rheumatoid ArthritisA 
Randomized, Controlled Trial. Annals of internal medicine, 1999. 
130(6): p. 478-486. 
96. Cao, S., et al., Lentiviral vector-mediated stable expression of 
sTNFR-Fc in human macrophage and neuronal cells as a potential 
therapy for neuroAIDS. Journal of neuroinflammation, 2011. 8(1): p. 48. 
	 154 
97. Zhao, Y., et al., GDNF-transfected macrophages produce potent 
neuroprotective effects in Parkinson's disease mouse model. PloS one, 
2014. 9(9): p. e106867. 
98. Ramaswamy, S., K.E. Soderstrom, and J.H. Kordower, Trophic factors 
therapy in Parkinson's disease. Progress in brain research, 2009. 175: 
p. 201-216. 
99. Kordower, J.H., et al., Neurodegeneration prevented by lentiviral vector 
delivery of GDNF in primate models of Parkinson's disease. Science, 
2000. 290(5492): p. 767-773. 
100. Cai, Y., et al., Interplay of endoplasmic reticulum stress and autophagy 
in neurodegenerative disorders. Autophagy, 2016. 12(2): p. 225-244. 
101. Garcia-Huerta, P., et al., The intersection between growth factors, 
autophagy and ER stress: A new target to treat neurodegenerative 
diseases? Brain research, 2016. 1649: p. 173-180. 
102. Shi, S., Z. Wang, and Z. Qiao, The multifunctional anti-inflammatory 
drugs used in the therapy of Alzheimer’s disease. Current medicinal 
chemistry, 2013. 20(20): p. 2583-2588. 
103. Tobinick, E., et al., TNF-alpha modulation for treatment of Alzheimer's 
disease: a 6-month pilot study. MedGenMed, 2006. 8(2): p. 25. 
104. Wiley, C.A., et al., Cellular localization of human immunodeficiency 
virus infection within the brains of acquired immune deficiency 
	 155 
syndrome patients. Proceedings of the National Academy of Sciences, 
1986. 83(18): p. 7089-7093. 
105. Ginhoux, F., et al., Fate mapping analysis reveals that adult microglia 
derive from primitive macrophages. Science, 2010. 330(6005): p. 
841-845. 
106. Yona, S., et al., Fate mapping reveals origins and dynamics of 
monocytes and tissue macrophages under homeostasis. Immunity, 
2013. 38(1): p. 79-91. 
107. Schulz, C., et al., A lineage of myeloid cells independent of Myb and 
hematopoietic stem cells. Science, 2012. 336(6077): p. 86-90. 
108. Prinz, M. and J. Priller, Microglia and brain macrophages in the 
molecular age: from origin to neuropsychiatric disease. Nature Reviews 
Neuroscience, 2014. 15(5): p. 300-312. 
109. Persidsky, Y., et al., Microglial and astrocyte chemokines regulate 
monocyte migration through the blood-brain barrier in human 
immunodeficiency virus-1 encephalitis. The American journal of 
pathology, 1999. 155(5): p. 1599-1611. 
110. Gorantla, S., L. Poluektova, and H.E. Gendelman, Rodent models for 
HIV-associated neurocognitive disorders. Trends in neurosciences, 
2012. 35(3): p. 197-208. 
	 156 
111. Churchill, M.J., et al., Extensive astrocyte infection is prominent in 
human immunodeficiency virus–associated dementia. Annals of 
neurology, 2009. 66(2): p. 253-258. 
112. Churchill, M.J., et al., Use of laser capture microdissection to detect 
integrated HIV-1 DNA in macrophages and astrocytes from autopsy 
brain tissues. Journal of neurovirology, 2006. 12(2): p. 146-152. 
113. Gorry, P.R., et al., Astrocyte infection by HIV-1: mechanisms of 
restricted virus replication, and role in the pathogenesis of 
HIV-1-associated dementia. Current HIV research, 2003. 1(4): p. 
463-473. 
114. Trillo‐Pazos, G., et al., Detection of HIV‐1 DNA in 
microglia/macrophages, astrocytes and neurons isolated from brain 
tissue with HIV‐1 encephalitis by laser capture microdissection. Brain 
pathology, 2003. 13(2): p. 144-154. 
115. An, S.F., et al., Early entry and widespread cellular involvement of 
HIV-1 DNA in brains of HIV-1 positive asymptomatic individuals. Journal 
of Neuropathology & Experimental Neurology, 1999. 58(11): p. 
1156-1162. 
116. Russell, R.A., et al., Astrocytes Resist HIV-1 Fusion but Engulf Infected 
Macrophage Material. Cell Reports, 2017. 18(6): p. 1473-1483. 
	 157 
117. Mohri, H., et al., Rapid turnover of T lymphocytes in SIV-infected rhesus 
macaques. Science, 1998. 279(5354): p. 1223-1227. 
118. Browning, J., et al., Mice transgenic for human CD4 and CCR5 are 
susceptible to HIV infection. Proceedings of the National Academy of 
Sciences, 1997. 94(26): p. 14637-14641. 
119. Perez-Caballero, D., et al., Tetherin inhibits HIV-1 release by directly 
tethering virions to cells. Cell, 2009. 139(3): p. 499-511. 
120. Laguette, N., et al., SAMHD1 is the dendritic-and myeloid-cell-specific 
HIV-1 restriction factor counteracted by Vpx. Nature, 2011. 474(7353): 
p. 654-657. 
121. Potash, M. and D. Volsky, Development of a murine model of HIV-1 
infection on the basis of construction of EcoHIV, a chimeric, molecular 
clone of human immunodeficiency virus type 1 and ecotropic moloney 
murine leukemia virus competent to infect murine cells and mice. 2005, 
Google Patents. 
122. Bansal, A.K., et al., Neurotoxicity of HIV-1 proteins gp120 and Tat in the 
rat striatum. Brain research, 2000. 879(1): p. 42-49. 
123. Dickie, P., et al., HIV-associated nephropathy in transgenic mice 
expressing HIV-1 genes. Virology, 1991. 185(1): p. 109-119. 
124. D'Aversa, T., E. Eugenin, and J.W. Berman, NeuroAIDS: Contributions 
of the human immunodeficiency virus‐1 proteins tat and gp120 as well 
	 158 
as CD40 to microglial activation. Journal of neuroscience research, 
2005. 81(3): p. 436-446. 
125. Vezzani, A. and B. Viviani, Neuromodulatory properties of inflammatory 
cytokines and their impact on neuronal excitability. 
Neuropharmacology, 2015. 96: p. 70-82. 
126. Rao, J.S., et al., Increased neuroinflammatory and arachidonic acid 
cascade markers, and reduced synaptic proteins, in brain of HIV-1 
transgenic rats. Journal of neuroinflammation, 2011. 8(1): p. 101. 
127. Royal, W., et al., Immune activation, viral gene product expression and 
neurotoxicity in the HIV-1 transgenic rat. Journal of neuroimmunology, 
2012. 247(1): p. 16-24. 
128. Tran, P.B., D. Ren, and R.J. Miller, The HIV-1 coat protein gp120 
regulates CXCR4-mediated signaling in neural progenitor cells. Journal 
of neuroimmunology, 2005. 160(1): p. 68-76. 
129. Bardi, G., et al., Human immunodeficiency virus gp120-induced 
apoptosis of human neuroblastoma cells in the absence of CXCR4 
internalization. Journal of neurovirology, 2006. 12(3): p. 211-218. 
130. Catani, M.V., et al., gp120 induces cell death in human neuroblastoma 
cells through the CXCR4 and CCR5 chemokine receptors. Journal of 
neurochemistry, 2000. 74(6): p. 2373-2379. 
	 159 
131. Fitting, S., et al., Synaptic dysfunction in the hippocampus accompanies 
learning and memory deficits in human immunodeficiency virus type-1 
Tat transgenic mice. Biological psychiatry, 2013. 73(5): p. 443-453. 
132. Kim, B.O., et al., Neuropathologies in transgenic mice expressing 
human immunodeficiency virus type 1 Tat protein under the regulation 
of the astrocyte-specific glial fibrillary acidic protein promoter and 
doxycycline. The American journal of pathology, 2003. 162(5): p. 
1693-1707. 
133. Liu, Y., et al., Uptake of HIV-1 tat protein mediated by low-density 
lipoprotein receptor-related protein disrupts the neuronal metabolic 
balance of the receptor ligands. Nature medicine, 2000. 6(12): p. 
1380-1387. 
134. Haughey, N., et al., HIV‐1 Tat through phosphorylation of NMDA 
receptors potentiates glutamate excitotoxicity. Journal of 
neurochemistry, 2001. 78(3): p. 457-467. 
135. Hargus, N.J. and S.A. Thayer, Human immunodeficiency virus-1 Tat 
protein increases the number of inhibitory synapses between 
hippocampal neurons in culture. Journal of Neuroscience, 2013. 33(45): 
p. 17908-17920. 
	 160 
136. Power, C., et al., Delineating HIV-associated neurocognitive disorders 
using transgenic models: the neuropathogenic actions of Vpr. Journal of 
Neuroimmune Pharmacology, 2012. 7(2): p. 319-331. 
137. Chompre, G., et al., Astrocytic expression of HIV-1 Nef impairs spatial 
and recognition memory. Neurobiology of disease, 2013. 49: p. 
128-136. 
138. Torres, L. and R.J. Noel, Astrocytic expression of HIV-1 viral protein R 
in the hippocampus causes chromatolysis, synaptic loss and memory 
impairment. Journal of neuroinflammation, 2014. 11(1): p. 53. 
139. Hok, V., et al., Spatial cognition in mice and rats: similarities and 
differences in brain and behavior. Wiley Interdisciplinary Reviews: 
Cognitive Science, 2016. 7(6): p. 406-421. 
140. Gendelman, H.E., et al., Immunopathogenesis of human 
immunodeficiency virus infection in the central nervous system. Annals 
of neurology, 1988. 23(S1). 
141. Tyor, W.R., et al., A model of human immunodeficiency virus 
encephalitis in scid mice. Proceedings of the National Academy of 
Sciences, 1993. 90(18): p. 8658-8662. 
142. Persidsky, Y., et al., Human immunodeficiency virus encephalitis in 
SCID mice. The American journal of pathology, 1996. 149(3): p. 1027. 
	 161 
143. Avgeropoulos, N., et al., SCID mice with HIV encephalitis develop 
behavioral abnormalities. JAIDS Journal of Acquired Immune 
Deficiency Syndromes, 1998. 18(1): p. 13-20. 
144. Anderson, E., et al., Hippocampal synaptic dysfunction in a murine 
model of human immunodeficiency virus type 1 encephalitis. 
Neuroscience, 2003. 118(2): p. 359-369. 
145. Xiong, H., et al., HIV-1 infected mononuclear phagocyte secretory 
products affect neuronal physiology leading to cellular demise: 
relevance for HIV-1-associated dementia. Journal of neurovirology, 
2000. 6(1): p. S14. 
146. Limoges, J., et al., The efficacy of potent anti-retroviral drug 
combinations tested in a murine model of HIV-1 encephalitis. Virology, 
2001. 281(1): p. 21-34. 
147. Spitzenberger, T.J., et al., Novel delivery system enhances efficacy of 
antiretroviral therapy in animal model for HIV-1 encephalitis. Journal of 
Cerebral Blood Flow & Metabolism, 2007. 27(5): p. 1033-1042. 
148. Dou, H., et al., Neuroprotective mechanisms of lithium in murine human 
immunodeficiency virus-1 encephalitis. Journal of Neuroscience, 2005. 
25(37): p. 8375-8385. 
	 162 
149. Dou, H., et al., Neuroprotective activities of sodium valproate in a 
murine model of human immunodeficiency virus-1 encephalitis. Journal 
of Neuroscience, 2003. 23(27): p. 9162-9170. 
150. Denton, P.W., et al., Generation of HIV latency in BLT humanized mice. 
Journal of virology, 2011: p. JVI. 06120-11. 
151. Denton, P.W., et al., Targeted cytotoxic therapy kills persisting HIV 
infected cells during ART. PLoS Pathog, 2014. 10(1): p. e1003872. 
152. Wahl, A., et al., Human breast milk and antiretrovirals dramatically 
reduce oral HIV-1 transmission in BLT humanized mice. PLoS Pathog, 
2012. 8(6): p. e1002732. 
153. Brehm, M.A., et al., Parameters for establishing humanized mouse 
models to study human immunity: analysis of human hematopoietic 
stem cell engraftment in three immunodeficient strains of mice bearing 
the IL2rγ null mutation. Clinical immunology, 2010. 135(1): p. 84-98. 
154. Gorantla, S., et al., Links between progressive HIV-1 infection of 
humanized mice and viral neuropathogenesis. The American journal of 
pathology, 2010. 177(6): p. 2938-2949. 
155. Nie, C., et al., Selective infection of CD4+ effector memory T 
lymphocytes leads to preferential depletion of memory T lymphocytes in 
R5 HIV-1-infected humanized NOD/SCID/IL-2Rγ null mice. Virology, 
2009. 394(1): p. 64-72. 
	 163 
156. Lepus, C.M., et al., Comparison of human fetal liver, umbilical cord 
blood, and adult blood hematopoietic stem cell engraftment in 
NOD-scid/γc−/−, Balb/c-Rag1−/− γc−/−, and CB-17-scid/bg 
immunodeficient mice. Human immunology, 2009. 70(10): p. 790-802. 
157. Dudek, T.E., et al., Rapid evolution of HIV-1 to functional CD8+ T cell 
responses in humanized BLT mice. Science translational medicine, 
2012. 4(143): p. 143ra98-143ra98. 
158. Watanabe, S., et al., Hematopoietic stem cell–engrafted 
NOD/SCID/IL2Rγnull mice develop human lymphoid systems and 
induce long-lasting HIV-1 infection with specific humoral immune 
responses. Blood, 2007. 109(1): p. 212-218. 
159. Horwitz, J.A., et al., HIV-1 suppression and durable control by 
combining single broadly neutralizing antibodies and antiretroviral drugs 
in humanized mice. Proceedings of the National Academy of Sciences, 
2013. 110(41): p. 16538-16543. 
160. Halper-Stromberg, A., et al., Broadly neutralizing antibodies and viral 
inducers decrease rebound from HIV-1 latent reservoirs in humanized 
mice. Cell, 2014. 158(5): p. 989-999. 
161. Liner II, K.J., M.J. Ro, and K.R. Robertson, HIV, antiretroviral therapies, 
and the brain. Current HIV/AIDS Reports, 2010. 7(2): p. 85-91. 
	 164 
162. Dash, P.K., et al., Long-acting nanoformulated antiretroviral therapy 
elicits potent antiretroviral and neuroprotective responses in 
HIV-1-infected humanized mice. AIDS (London, England), 2012. 
26(17): p. 2135-2144. 
163. Jaeger, L.B. and A. Nath, Modeling HIV-associated neurocognitive 
disorders in mice: new approaches in the changing face of HIV 
neuropathogenesis. Disease models & mechanisms, 2012. 5(3): p. 
313-322. 
164. Roy, N.S., et al., Functional engraftment of human ES cell–derived 
dopaminergic neurons enriched by coculture with 
telomerase-immortalized midbrain astrocytes. Nature medicine, 2006. 
12(11): p. 1259-1268. 
165. Tamaki, S., et al., Engraftment of sorted/expanded human central 
nervous system stem cells from fetal brain. Journal of neuroscience 
research, 2002. 69(6): p. 976-986. 
166. Nunes, M.C., et al., Identification and isolation of multipotential neural 
progenitor cells from the subcortical white matter of the adult human 
brain. Nature medicine, 2003. 9(4): p. 439-447. 
167. Emborg, M., et al., Response of aged parkinsonian monkeys to in vivo 
gene transfer of GDNF. Neurobiology of disease, 2009. 36(2): p. 
303-311. 
	 165 
168. Windrem, M.S., et al., A competitive advantage by neonatally engrafted 
human glial progenitors yields mice whose brains are chimeric for 
human glia. Journal of Neuroscience, 2014. 34(48): p. 16153-16161. 
169. Han, X., et al., Forebrain engraftment by human glial progenitor cells 
enhances synaptic plasticity and learning in adult mice. Cell stem cell, 
2013. 12(3): p. 342-353. 
170. Gao, J., et al., Transplantation of primed human fetal neural stem cells 
improves cognitive function in rats after traumatic brain injury. Exp 
Neurol, 2006. 201(2): p. 281-292. 
171. Han, X., et al., Forebrain engraftment by human glial progenitor cells 
enhances synaptic plasticity and learning in adult mice. Cell Stem Cell, 
2013. 12(3): p. 342-53. 
172. Windrem, M.S., et al., A competitive advantage by neonatally engrafted 
human glial progenitors yields mice whose brains are chimeric for 
human glia. J Neurosci, 2014. 34(48): p. 16153-61. 
173. Kierdorf, K., et al., Microglia emerge from erythromyeloid precursors via 
Pu. 1-and Irf8-dependent pathways. Nature neuroscience, 2013. 16(3): 
p. 273-280. 
174. Wang, Y., et al., IL-34 is a tissue-restricted ligand of CSF1R required for 
the development of Langerhans cells and microglia. Nature 
immunology, 2012. 13(8): p. 753-760. 
	 166 
175. Wei, S., et al., Functional overlap but differential expression of CSF-1 
and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. 
Journal of leukocyte biology, 2010. 88(3): p. 495-505. 
176. Gelman, B.B., et al., The National NeuroAIDS Tissue Consortium brain 
gene array: two types of HIV-associated neurocognitive impairment. 
PloS one, 2012. 7(9): p. e46178. 
177. Saylor, D., et al., HIV-associated neurocognitive disorder--pathogenesis 
and prospects for treatment. Nat Rev Neurol, 2016. 12(4): p. 234-48. 
178. Gorantla, S., L. Poluektova, and H.E. Gendelman, Rodent models for 
HIV-associated neurocognitive disorders. Trends Neurosci, 2012. 
35(3): p. 197-208. 
179. Narayan, O. and J.E. Clements, Biology and pathogenesis of 
lentiviruses. J Gen Virol, 1989. 70 ( Pt 7): p. 1617-39. 
180. Jaeger, L.B. and A. Nath, Modeling HIV-associated neurocognitive 
disorders in mice: new approaches in the changing face of HIV 
neuropathogenesis. Dis Model Mech, 2012. 5(3): p. 313-22. 
181. Dash, P.K., et al., Loss of neuronal integrity during progressive HIV-1 
infection of humanized mice. J Neurosci, 2011. 31(9): p. 3148-57. 
182. Gorantla, S., et al., Links between progressive HIV-1 infection of 
humanized mice and viral neuropathogenesis. Am J Pathol, 2010. 
177(6): p. 2938-2949. 
	 167 
183. Boska, M.D., et al., Associations between brain microstructures, 
metabolites, and cognitive deficits during chronic HIV-1 infection of 
humanized mice. Mol Neurodegener, 2014. 9: p. 58. 
184. Oberheim, N.A., et al., Uniquely hominid features of adult human 
astrocytes. J Neurosci, 2009. 29(10): p. 3276-87. 
185. Farina, C., F. Aloisi, and E. Meinl, Astrocytes are active players in 
cerebral innate immunity. Trends Immunol, 2007. 28(3): p. 138-145. 
186. Pfefferkorn, C., et al., Abortively Infected Astrocytes Appear To 
Represent the Main Source of Interferon Beta in the Virus-Infected 
Brain. J Virol, 2016. 90(4): p. 2031-8. 
187. Chauhan, A., Enigma of HIV-1 latent infection in astrocytes: an in-vitro 
study using protein kinase C agonist as a latency reversing agent. 
Microbes Infect, 2015. 17(9): p. 651-9. 
188. Churchill, M. and A. Nath, Where does HIV hide? A focus on the central 
nervous system. Curr Opin HIV AIDS, 2013. 8(3): p. 165-9. 
189. Tornatore, C., et al., HIV‐1 infection of subcortical astrocytes in the 
pediatric central nervous system. Neurology, 1994. 44(3 Part 1): p. 
481-481. 
190. Gonzalez-Scarano, F. and J. Martin-Garcia, The neuropathogenesis of 
AIDS. Nat Rev Immunol, 2005. 5(1): p. 69-81. 
	 168 
191. Gorantla, S., et al., Human immunodeficiency virus type 1 pathobiology 
studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol, 2007. 
81(6): p. 2700-12. 
192. Arainga, M., et al., HIV-1 cellular and tissue replication patterns in 
infected humanized mice. Sci Rep, 2016. 6: p. 23513. 
193. Carpenter, M.K., et al., In vitro expansion of a multipotent population of 
human neural progenitor cells. Exp Neurol, 1999. 158(2): p. 265-278. 
194. Uchida, N., et al., Direct isolation of human central nervous system 
stem cells. Proc Natl Acad Sci U S A, 2000. 97(26): p. 14720-5. 
195. Tamaki, S., et al., Engraftment of sorted/expanded human central 
nervous system stem cells from fetal brain. J Neurosci Res, 2002. 
69(6): p. 976-86. 
196. Nunes, M.C., et al., Identification and isolation of multipotential neural 
progenitor cells from the subcortical white matter of the adult human 
brain. Nat Med, 2003. 9(4): p. 439-447. 
197. Qian, X., et al., Timing of CNS cell generation: a programmed sequence 
of neuron and glial cell production from isolated murine cortical stem 
cells. Neuron, 2000. 28(1): p. 69-80. 
198. Elkabetz, Y., et al., Human ES cell-derived neural rosettes reveal a 
functionally distinct early neural stem cell stage. Genes Dev, 2008. 
22(2): p. 152-65. 
	 169 
199. Oberheim, N.A., et al., Astrocytic complexity distinguishes the human 
brain. Trends in neurosciences, 2006. 29(10): p. 547-553. 
200. Trapnell, C., et al., Differential gene and transcript expression analysis 
of RNA-seq experiments with TopHat and Cufflinks. Nature Protocols, 
2012. 7(3): p. 562-578. 
201. Steinman, R.M., The dendritic cell system and its role in 
immunogenicity. Annu Rev Immunol, 1991. 9: p. 271-96. 
202. Sabri, F., et al., Astrocyte activation and apoptosis: their roles in the 
neuropathology of HIV infection. Brain Pathol, 2003. 13(1): p. 84-94. 
203. Schweighardt, B. and W.J. Atwood, HIV type 1 infection of human 
astrocytes is restricted by inefficient viral entry. AIDS Res Hum 
Retroviruses, 2001. 17(12): p. 1133-42. 
204. Boutet, A., et al., Isolated human astrocytes are not susceptible to 
infection by M‐and T‐tropic HIV‐1 strains despite functional 
expression of the chemokine receptors CCR5 and CXCR4. Glia, 2001. 
34(3): p. 165-177. 
205. Morton, J.J., et al., XactMice: humanizing mouse bone marrow enables 
microenvironment reconstitution in a patient-derived xenograft model of 
head and neck cancer. Oncogene, 2016. 35(3): p. 290-300. 
	 170 
206. Weidner, C., et al., Defining the optimal animal model for translational 
research using gene set enrichment analysis. EMBO Mol Med, 2016. 
8(8): p. 831-8. 
207. Cheon, H., et al., IFNβ‐dependent increases in STAT1, STAT2, and 
IRF9 mediate resistance to viruses and DNA damage. EMBO J, 2013. 
32(20): p. 2751-2763. 
208. Aaronson, D.S. and C.M. Horvath, A road map for those who don't know 
JAK-STAT. Science, 2002. 296(5573): p. 1653-1655. 
209. Lu, J., et al., The IFITM proteins inhibit HIV-1 infection. J Virol, 2011. 
85(5): p. 2126-2137. 
210. Fricke, T., et al., MxB binds to the HIV-1 core and prevents the 
uncoating process of HIV-1. Retrovirology, 2014. 11(1): p. 1. 
211. Okumura, A., et al., Innate antiviral response targets HIV-1 release by 
the induction of ubiquitin-like protein ISG15. Proc Natl Acad Sci U S A, 
2006. 103(5): p. 1440-1445. 
212. Espert, L., et al., Interferon-induced exonuclease ISG20 exhibits an 
antiviral activity against human immunodeficiency virus type 1. J  Gen 
Virol, 2005. 86(8): p. 2221-2229. 
213. Spragg, C.J. and M. Emerman, Antagonism of SAMHD1 is actively 
maintained in natural infections of simian immunodeficiency virus. 
	 171 
Proceedings of the National Academy of Sciences, 2013. 110(52): p. 
21136-21141. 
214. Rivieccio, M.A., et al., TLR3 ligation activates an antiviral response in 
human fetal astrocytes: a role for viperin/cig5. J Immunol, 2006. 177(7): 
p. 4735-4741. 
215. Nasr, N., et al., HIV-1 infection of human macrophages directly induces 
viperin which inhibits viral production. Blood, 2012. 120(4): p. 778-788. 
216. Neil, S.J., T. Zang, and P.D. Bieniasz, Tetherin inhibits retrovirus 
release and is antagonized by HIV-1 Vpu. Nature, 2008. 451(7177): p. 
425-430. 
217. Lazear, H.M., et al., IRF-3, IRF-5, and IRF-7 coordinately regulate the 
type I IFN response in myeloid dendritic cells downstream of MAVS 
signaling. PLoS Pathog, 2013. 9(1): p. e1003118. 
218. Thompson, K.A., J.C. McArthur, and S.L. Wesselingh, Correlation 
between neurological progression and astrocyte apoptosis in HIV‐
associated dementia. Ann Neurol, 2001. 49(6): p. 745-752. 
219. Monroe, K.M., et al., IFI16 DNA sensor is required for death of lymphoid 
CD4 T cells abortively infected with HIV. Science, 2014. 343(6169): p. 
428-432. 
	 172 
220. Suzuki, Y., et al., Characterization of RyDEN (C19orf66) as an 
Interferon-Stimulated Cellular Inhibitor against Dengue Virus 
Replication. PLoS Pathog, 2016. 12(1): p. e1005357. 
221. Calabrese, G., et al., The gene (LGALS3BP) encoding the serum 
protein 90K, associated with cancer and infection by the human 
immunodeficiency virus, maps at 17q25. Cytogenet Cell Genet, 1995. 
69(3-4): p. 223-5. 
222. Wang, S.-Z., et al., An oligodendrocyte-specific zinc-finger transcription 
regulator cooperates with Olig2 to promote oligodendrocyte 
differentiation. Development, 2006. 133(17): p. 3389-3398. 
223. Morita, K., et al., Claudin-11/OSP-based tight junctions of myelin 
sheaths in brain and Sertoli cells in testis. J Cell Biol, 1999. 145(3): p. 
579-88. 
224. Gow, A., et al., CNS myelin and sertoli cell tight junction strands are 
absent in Osp/claudin-11 null mice. Cell, 1999. 99(6): p. 649-59. 
225. Li, M.D., et al., Transcriptome sequencing of gene expression in the 
brain of the HIV-1 transgenic rat. PLoS One, 2013. 8(3): p. e59582. 
226. Borjabad, A., et al., Significant effects of antiretroviral therapy on global 
gene expression in brain tissues of patients with HIV-1-associated 
neurocognitive disorders. PLoS Pathog, 2011. 7(9): p. e1002213. 
	 173 
227. Gendelman, H.E., et al., Efficient isolation and propagation of human 
immunodeficiency virus on recombinant colony-stimulating factor 
1-treated monocytes. J Exp Med, 1988. 167(4): p. 1428-1441. 
228. Nath, A., et al., Infection of human fetal astrocytes with HIV-1: viral 
tropism and the role of cell to cell contact in viral transmission. J 
Neuropathol Exp Neurol, 1995. 54(3): p. 320-30. 
229. Chen, C., et al., Role of astroglia in Down’s syndrome revealed by 
patient-derived human-induced pluripotent stem cells. Nature 
communications, 2014. 5. 
230. Macosko, E.Z., et al., Highly parallel genome-wide expression profiling 
of individual cells using nanoliter droplets. Cell, 2015. 161(5): p. 
1202-1214. 
231. Zhen, A., et al., Targeting type I interferon–mediated activation restores 
immune function in chronic HIV infection. The Journal of Clinical 
Investigation, 2016. 127(1). 
232. Cheng, L., et al., Blocking type I interferon signaling enhances T cell 
recovery and reduces HIV-1 reservoirs. The Journal of Clinical 
Investigation, 2017. 127(1): p. 269-279. 
233. Deeks, S.G., P.M. Odorizzi, and R.-P. Sekaly, The interferon paradox: 
can inhibiting an antiviral mechanism advance an HIV cure? The 
Journal of clinical investigation, 2017. 127(1): p. 103. 
